

## AAT DEFICIENCY

---

### Products Affected

- Aralast NP
- Glassia
- Prolastin-C
- Zemaira

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of severe congenital A1-PI deficiency who have clinically evident emphysema, weight, A1-PI phenotype, A1-PI baseline level
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by a pulmonologist
<b>Coverage Duration</b>	6 months for initiation, 1 year for continuation
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## ADAPALENE

---

### Products Affected

- adapalene topical cream
- adapalene topical gel
- adapalene topical solution
- adapalene topical swab

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Not approved when used to treat photo aging.
<b>Required Medical Information</b>	Diagnosis, previous treatments, and response therapy
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Must have failure, intolerance, or contraindication to tretinoin
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## ADEMPAS

---

### Products Affected

- Adempas

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Confirmation of diagnosis, documentation of response to any prior therapies
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by pulmonologist or cardiologist
<b>Coverage Duration</b>	3 months initial, 1 year continuation
<b>Other Criteria</b>	For WHO Group 1 diagnosis, patient must have a history of taking or contraindication to sildenafil (Revatio).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## AFINITOR

---

### Products Affected

- Afinitor Disperz
- Afinitor oral tablet 10 mg
- everolimus (antineoplastic)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	DIAGNOSIS, PRIOR THERAPIES, AND TREATMENT RESPONSE
Age Restrictions	N/A
Prescriber Restrictions	PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST OR NEUROLOGIST
Coverage Duration	2 years
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

## AIMOVIG

---

### Products Affected

- Aimovig Autoinjector

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies tried, and outcome. Member has been evaluated for and does not have medication overuse headache.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Under CMS Review.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Patient must have an inadequate response, contraindication, or intolerance to two different chronic migraine prevention drugs. The two prerequisite drugs must be from different classes such as anticonvulsants (topiramate/valproate), beta blockers (propranolol, metoprolol), and antidepressants (nortriptyline/venlafaxine).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## ALK POSITIVE TYROSINE KINASE INHIBITORS

---

### Products Affected

- Alecensa
- Xalkori
- Zykadia oral tablet

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, other treatments tried and outcome
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by an oncologist
Coverage Duration	2 years
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

## ALUNBRIG

---

### Products Affected

- Alunbrig

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Under CMS Review.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Approve for continuation of prior therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## AMIFAMPRIDINE

---

### Products Affected

- Firdapse
- Ruzurgi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Must have a documented diagnosis of Lamber-Eaton with electrodiagnostic studies including repetitive nerve stimulation and anti-P/Q-type voltage-gated calcium channel (VGCC) antibody testing to confirm the diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by a neurologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## AMPYRA

---

### Products Affected

- dalfampridine

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	NOT A COVERED BENEFIT IN PATIENTS WITH SEIZURE DISORDER OR A CREATININE CLEARANCE LESS THAN 50 ML/MIN
<b>Required Medical Information</b>	EXPANDED DISABILITY SCALE SCORE, BASELINE AND FOLLOW-UP 25 FOOT WALK TEST, CREATININE CLEARANCE
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY A NEUROLOGIST
<b>Coverage Duration</b>	3 MONTHS INITIAL, 1 YEAR CONTINUATION
<b>Other Criteria</b>	PATIENT MUST SHOW AN IMPROVEMENT IN WALKING SPEED TO CONTINUE TREATMENT
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## ANALEPTIC

---

### Products Affected

- armodafinil
- modafinil

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Under CMS Review.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Excessive sleepiness due to SWSD defined as the patient is working at least 5 overnight shifts per month. As adjunctive/augmentation treatment for depression in the adult if the patient is concurrently receiving other medication therapy for depression.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## ANTIDEPRESSANTS

### Products Affected

- Drizalma Sprinkle oral capsule, delayed rel sprinkle 20 mg, 30 mg, 40 mg, 60 mg
- Fetzima
- Trintellix
- Viibryd oral tablet
- Viibryd oral tablets, dose pack 10 mg (7)-20 mg (23)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	DIAGNOSIS, PRIOR THERAPIES TRIED AND FAILED
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	2 years
Other Criteria	Under CMS Review.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

## ANTIPSYCHOTICS

### Products Affected

- Abilify Maintena
- Aristada
- Aristada Initio
- Caplyta
- chlorpromazine injection
- Fanapt
- Invega Sustenna
- Invega Trinza
- Latuda oral tablet 120 mg, 20 mg, 40 mg, 60 mg, 80 mg
- Rexulti
- Saphris
- Secuado
- Versacloz
- Vraylar oral capsule
- Vraylar oral capsule,dose pack

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	FOR BIPOLAR DISORDER OR SCHIZOPHRENIA, DOCUMENTATION OF DIAGNOSIS, TREATMENT FAILURE WITH TWO ATYPICAL ANTIPSYCHOTICS (ZIPRASIDONE, RISPERIDONE, QUETIAPINE, OLANZAPINE, CLOZAPINE), OR RATIONALE AS TO WHY ALTERNATIVES ARE NOT SUITABLE
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## APOKYN

---

### Products Affected

- APOKYN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior treatments, and outcome
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by neurologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Treatment failure or intolerance to Inbrija and carbidopa/levodopa ER
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## APREPITANT

---

### Products Affected

- aprepitant

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	For use with highly and moderately-emetogenic chemotherapy, provide the chemotherapy regimen including drug, dose, and frequency. Ondansetron is preferred for post-operative nausea/vomiting (PONV) prophylaxis. When aprepitant is used for PONV prophylaxis, provide rationale as to why ondansetron is not a suitable alternative.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	Request will also be reviewed for coverage under part B versus part D.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## ARCALYST

---

### Products Affected

- Arcalyst

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 YEAR AT A TIME
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## AURYXIA

---

### Products Affected

- Auryxia

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Not approved for treatment of iron deficiency anemia in patients with ESRD on dialysis.
<b>Required Medical Information</b>	Under CMS Review.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by a nephrologist.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Under CMS Review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## AYVAKIT

---

### Products Affected

- Ayvakit

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to avapritinib.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist or gastroenterologist.
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Documentation of a PDGFRA exon 18 mutation or PDGFRA D842V mutation.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## BALVERSA

---

### Products Affected

- Balversa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior treatments, and outcome
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## BENLYSTA

---

### Products Affected

- Benlysta subcutaneous syringe

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Severe active lupus nephritis, active central nervous, use in combination with other biologics
<b>Required Medical Information</b>	Diagnosis, autoantibody testing, prior treatments including response, and SLEDAI score.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescription must be written by a rheumatologist
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	Failed to demonstrate adequate response to TWO standard therapies at recommended doses: corticosteroids, antimalarials, NSAIDs, and/or immunosuppressants. SLEDAI score greater than 8.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## BOSULIF

---

### Products Affected

- Bosulif oral tablet 100 mg, 400 mg, 500 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to bosutinib. CBC and LFT lab test results are needed for continuation treatment.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## BRAFTOVI

---

### Products Affected

- Braftovi oral capsule 75 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to treatment.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## BRIVIACT

---

### Products Affected

- Briviacet oral

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used and result of prior therapy. If continuation, response to brivaracetam.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescription must be written by neurologist.
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	Failure of treatment with levetiracetam and ONE additional Part D formulary anticonvulsant drug.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## BRUKINSA

---

### Products Affected

- Brukinsa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapies, and result of prior therapy.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescription must be written by hematologist/oncologist.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## CABOMETYX

---

### Products Affected

- Cabometyx

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Renal cell carcinoma (RCC): Diagnosis of RCC. RCC is advanced. History of failure, contraindication, or intolerance to at least one prior anti-angiogenic therapy [e.g., Nexavar (sorafenib), Sutent (sunitinib)].
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist.
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## CALQUENCE

---

### Products Affected

- Calquence

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	NA
<b>Required Medical Information</b>	Documentation of diagnosis, previous treatments, and response to treatment.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by oncology
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## CAPRELSA

---

### Products Affected

- Caprelsa oral tablet 100 mg, 300 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	HISTORY OF CONGENITAL LONG QT SYNDROME
<b>Required Medical Information</b>	DIAGNOSIS, PRIOR THERAPIES, TREATMENT RESPONSE
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	ECG, ELECTROLYTE(K,Mg,Ca), AND TSH MONITORING AT BASELINE, 2-4 WEEKS AND 8-12 WEEKS AFTER STARTING TREATMENT AND EVERY 3 MONTHS THEREAFTER
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## CINQAIR

---

### Products Affected

- Cinqair

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Administration of reslizumab requires a specialized care setting and requires an experienced clinician prepared to manage anaphylaxis will not be approved for self-administration
<b>Required Medical Information</b>	Allergen test, baseline FEV1, FEV1 following bronchodilator, asthma medical history (including medications, emergency department visits, and hospitalizations), baseline eosinophil count
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Pulmonology or Immunologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Patient must be diagnosed with severe asthma, currently receiving inhaled and/or oral corticosteroid treatment, have a baseline eosinophil count of 400/mcL, have a contraindication, intolerance or failure of Nucala.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## COMETRIQ

---

### Products Affected

- Cometriq

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## COPIKTRA

---

### Products Affected

- Copiktra

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to treatment.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist or hematologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## CORLANOR

---

### Products Affected

- Corlanor

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	For heart failure in adult patients, only: ejection fraction less than or equal to 35% AND heart rate greater than 70 beats per minute AND in sinus rhythm AND on maximally tolerated beta-blocker OR has contraindication to beta-blocker (i.e.. allergy, severe COPD limiting beta blocker usage).
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by a cardiologist.
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## COSENTYX

---

### Products Affected

- Cosentyx (2 Syringes)
- Cosentyx Pen (2 Pens)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other treatments tried and reasons for failure. Regular monitoring for TB required, both at baseline and during treatment
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescribing limited to a rheumatologist or dermatologist.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	For arthritis conditions, must have a trial of or contraindication to one non-biologic DMARD (methotrexate, hydroxychloroquine, sulfasalazine, azathioprine). For diagnosis of plaque psoriasis, must have a trial of or contraindication to cyclosporine or methotrexate.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## COTELLIC

---

### Products Affected

- Cotellic

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies tried and/or failed, and treatment response.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by an oncologist.
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## CROFELEMER

---

### Products Affected

- Mytesi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Use when infectious diarrhea has not been ruled out
<b>Required Medical Information</b>	Diagnosis, use of antiretroviral therapy
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Infectious diarrhea needs to be ruled out prior to initiating treatment. Patient must have a history of using at least two prior treatments for diarrhea, including bismuth subsalicylate, kaolin, loperamide, or diphenoxylate/atropine.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## DALIRESP

---

### Products Affected

- Daliresp

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Chronic Obstructive Pulmonary Disease (COPD), medications tried.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	COPD, approve in patients who meet all of the following conditions: Patients has severe COPD or very severe COPD, AND Patient has a history of exacerbations, AND Patient has tried a medication from two of the three following drug categories: long-acting beta2-agonist (LABA) [eg, salmeterol, indacaterol], long-acting muscarinic antagonist (LAMA) [eg, tiotropium], inhaled corticosteroid (eg, fluticasone).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## DAURISMO

---

### Products Affected

- Daurismo oral tablet 100 mg, 25 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapies, and result of prior therapy.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist or hematologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## DEMSEER

---

### Products Affected

- Demser

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis and whether the patient is a candidate for surgery
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## DICLOFENAC GEL 3%

---

### Products Affected

- diclofenac sodium topical gel 3 %

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis and any prior treatments.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by a Dermatologist
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## DOPTELET

---

### Products Affected

- Doptelet (10 tab pack)
- Doptelet (15 tab pack)
- Doptelet (30 tab pack)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis and platelet count
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Must be prescribed by a hematologist, oncologist, or gastroenterologist
<b>Coverage Duration</b>	1 month for chronic liver disease, 6 months for chronic immune thrombocytopenia
<b>Other Criteria</b>	For chronic liver disease-associated thrombocytopenia, the patient must be scheduled to undergo a pre planned medical or dental procedure with treatment beginning 10 to 13 days prior to the scheduled procedure. Patients should undergo their procedure 5 to 8 days after the last dose.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## DRONABINOL

---

### Products Affected

- dronabinol

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Not covered for the treatment of pain.
<b>Required Medical Information</b>	Diagnosis, previous treatments, and the outcome.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	For cancer related weight loss, must have a treatment failure or intolerance to megestrol.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## DUPIXENT

### Products Affected

- Dupixent Pen
- Dupixent Syringe subcutaneous syringe  
200 mg/1.14 mL, 300 mg/2 mL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Under CMS Review.
<b>Required Medical Information</b>	Diagnosis, prior therapy used and result of prior therapy. If continuation, response to dupilumab with documented reduction in number of acute exacerbations.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Under CMS Review.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	For atopic dermatitis: an adequate trial on at least one topical corticosteroid (fluticasone, fluocinonide, desonide) - and - one at least one topical immunomodulator (tacrolimus, pimecrolimus). For chronic rhinosinusitis with nasal polyps (CRS with NP), documentation of inflammatory persistence for 12 weeks or longer with and adequate trial of of a intranasal corticosteroid product (beclomethasone, fluticasone, mometasone) - and - an interleukine drug (montelukast, zafirlukast). For asthma, blood and/or tissue eosinophil testing with documentation of an adequate trial of an interleukine drug (montelukast, zafirlukast) - and - omalizumab.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## ENBREL

### Products Affected

- Enbrel Mini
- Enbrel subcutaneous recon soln
- Enbrel subcutaneous syringe
- Enbrel SureClick

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with biologic therapy or targeted synthetic DMARD
<b>Required Medical Information</b>	Diagnosis, concurrent medications, previous therapies tried.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	RA/AS/JIA/JRA, prescribed by or in consult w/ rheumatologist. PsA, prescribed by or in consultation w/ rheumatologist or dermatologist. PP, prescribed by or in consult w/ dermatologist. GVHD, prescribed by or in consult w/ oncologist, hematologist, or physician affiliated w/ transplant center. Behcet's disease, prescribed by or in consult w/ rheumatologist, dermatologist, ophthalmologist, gastroenterologist, or neurologist. Uveitis, prescribed by or in consultation with an ophthalmologist.
<b>Coverage Duration</b>	FDA approved indications - 3 months initial, 3 years cont, others 12 months.
<b>Other Criteria</b>	RA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic for RA are not required to step back and try a conventional synthetic DMARD). JIA/JRA, approve if the pt has aggressive disease, as determined by the prescriber, or the pt has tried one other agent for this condition (eg, MTX, sulfasalazine, leflunomide, NSAID, biologic DMARD or the pt will be started on Enbrel concurrently with MTX, sulfasalazine, or leflunomide or the pt has an absolute contraindication to MTX (eg, pregnancy, breast feeding, alcoholic liver disease, immunodeficiency syndrome, blood dyscrasias), sulfasalazine, or leflunomide. Plaque psoriasis (PP) initial approve if the patient meets one of the following conditions: 1) patient has tried at least one traditional systemic agent for at least 3 months for plaque psoriasis, unless intolerant (eg, MTX, cyclosporine, Soriatane, oral methoxsalen plus PUVA, (note: pts who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first)

<b>PA Criteria</b>	<b>Criteria Details</b>
	<p>OR 2) the patient has a contraindication to one oral agent for psoriasis such as MTX. GVHD. Tried or currently is receiving with etanercept 1 conventional GVHD tx (high-dose systemic corticosteroid, CSA, tacrolimus, MM, thalidomide, antithymocyte globulin, etc.). Behcet's. Has tried at least 1 conventional tx (eg, systemic corticosteroid, immunosuppressant, interferon alfa, MM, etc) or adalimumab or infliximab. Uveitis-tried one of the following: periocular, intraocular, or systemic corticosteroid, immunosuppressives, Humira or an infliximab product. RA/AS/JIA/PP/PsA Cont - must have a response to tx according to the prescriber. Behcet's, GVHD, Uveitis Cont-if the patient has had a response to tx according to the prescriber. Clinical criteria incorporated into the Enbrel 25 mg quantity limit edit, approve additional quantity (to allow for 50 mg twice weekly dosing) if one of the following is met: 1) Patient has plaque psoriasis, OR 2) Patient has RA/JIA/PsA/AS and is started and stabilized on 50 mg twice weekly dosing, OR 3) Patient has RA and the dose is being increased to 50 mg twice weekly and patient has taken MTX in combination with Enbrel 50 mg once weekly for at least 2 months, unless MTX is contraindicated or intolerant, OR 4) Patient has JIA/PsA/AS and the dose is being increased to 50 mg twice weekly after taking 50 mg once weekly for at least 2 months.</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## EPIDIOLEX

---

### Products Affected

- Epidiolex

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to treatment.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by or in consultation with a neurologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	For Lennox-Gastaut Syndrome: treatment failure or intolerance to valproate and lamotrigine. For Dravet Syndrome: treatment failure or intolerance to: valproate and topiramate.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## ERGOTAMINE DERIVATIVES

---

### Products Affected

- dihydroergotamine nasal

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior treatments and responses.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Under CMS Review.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	For treatment of migraine, trial and failure of one triptan (covered on the formulary) - AND - one oral migraine preventive medication in the anticonvulsant class (topiramate, valproate, divalproex) or beta blocker class (propranolol, metoprolol, timolol, atenolol, nadolol).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## ERIVEDGE

---

### Products Affected

- Erivedge

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PATIENTS WHO ARE CANDIDATES FOR SURGERY OR RADIATION
<b>Required Medical Information</b>	DIAGNOSIS, PRIOR TREATMENTS, RESPONSE TO THERAPY
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY A ONCOLOGIST OR DERMATOLOGIST
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## ERLEADA

---

### Products Affected

- Erleada

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies tried and outcome, fall risk assessment, and seizure history (if any)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Must be prescribed by an oncologist or urologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## ERYTHROPOIESIS STIMULATING AGENTS

### Products Affected

- Aranesp (in polysorbate) injection solution 100 mcg/mL, 200 mcg/mL, 25 mcg/mL, 300 mcg/mL, 40 mcg/mL, 60 mcg/mL
- Aranesp (in polysorbate) injection syringe
- Epogen injection solution 2,000 unit/mL, 20,000 unit/2 mL, 20,000 unit/mL, 3,000 unit/mL, 4,000 unit/mL
- Procrit injection solution 10,000 unit/mL, 2,000 unit/mL, 20,000 unit/mL, 3,000 unit/mL, 4,000 unit/mL, 40,000 unit/mL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Uncontrolled hypertension. Pure red cell aplasia that begins after ESA treatment.
<b>Required Medical Information</b>	Pre-treatment hemoglobin level less than 10 g/dL AND Patient has adequate iron stores prior to initiation of therapy defined as ferritin more than 100 mcg/L or serum transferrin saturation greater than 20% AND other causes of anemia such as iron deficiency, folate deficiency or B12 deficiency, hemolysis, gastrointestinal bleeding, other active or occult bleeding, or underlying hematologic disease (such as sickle cell anemia, thalassemia, and porphyria) have been ruled out.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	CKD - prescribed by a nephrologist or hematologist. Non-myeloid malignancies - prescribed by an oncologist/hematologist. Surgery - Prescribed by a surgeon. HIV - Prescribed by an infectious disease specialist.
<b>Coverage Duration</b>	Initial: 3 months. Renewal: CKD-12 months, Non-myeloid cancers, HIV-4 months. Surgery-3 months
<b>Other Criteria</b>	For renewal of CKD, for dialysis patients: Hb less than 11 g/dL or physician will decrease or interrupt dose and for non-dialysis patients: Hb less than 10 g/dL or physician will decrease or interrupt dose. For renewal of non-myeloid malignancies: Concurrent myelosuppressive chemotherapy and Hb is 12g/dL or less and there is measurable response after eight weeks (defined as an increase in Hb 1 g/dL or more or a reduction in red blood cell transfusion requirements). For renewal of zidovudine-treated HIV, Hb is 12g/dL or less AND Zidovudine dose remains 4,200 mg/week or less and there is a measurable response after eight weeks (defined as an increase in Hb or a reduction in RBC transfusion requirements or documented dose

Prior Authorization Criteria  
Health Alliance Plan 2021  
Date Effective: 01/01/2021

<b>PA Criteria</b>	<b>Criteria Details</b>
	escalation [up to max of 300 units/kg/dose])
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## EXJADE

### Products Affected

- deferasirox oral tablet, dispersible
- Exjade

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Serum ferritin, CrCl, serum transaminases and bilirubin, baseline auditory and ophthalmic examinations. For Non-Transfusion-Dependent Thalassemia Syndromes: liver iron concentration (LIC) by liver biopsy or by an FDA-cleared or approved method for identifying patients for treatment with deferasirox therapy. Dose verification
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	For chronic transfusional iron overload due to blood transfusion: serum ferritin consistently greater than 1000 mcg/L. For NON-transfusion dependent thalassemia syndrome and chronic iron overload a LIC (liver iron concentration) of at least 5 mg Fe/g dry weight and a serum ferritin greater than 300 mcg/L on at least 2 measurements 1 month apart. For patients continuation: current LIC is greater than 3 mg per gram of dry weight or Exjade (deferasirox) will be withheld until the LIC reaches above 5 mg per gram of dry weight.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## FARYDAK

---

### Products Affected

- Farydak

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies tried and/or failed
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## FASENRA

---

### Products Affected

- Fasenra
- Fasenra Pen

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Allergen test, baseline FEV1, FEV1 following bronchodilator, asthma medical history (including medications, emergency department visits, and hospitalizations), baseline eosinophil count
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Must be prescribed by a Pulmonologist or Immunologist or Allergist
<b>Coverage Duration</b>	Initiation: 3 months, continuation 1 year
<b>Other Criteria</b>	Patient must be diagnosed with severe asthma, currently receiving inhaled and/or oral corticosteroid treatment, AND have a baseline eosinophil count of 150 cells/mcL or greater within previous 12 months.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## FERRIPROX

---

### Products Affected

- Ferriprox oral tablet

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, length of therapy, serum ferritin concentrations and dose/weight verification, & CBC
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Must have a contraindication to, an inadequate response, or has been intolerant to, or experienced clinically significant adverse effects to Exjade, such as evidence of cardiac iron overload or iron-induced cardiac dysfunction with Exjade. For continuation patient must have a 20% or greater reduction in serum ferritin with an adequate dose and duration of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## FINTEPLA

---

### Products Affected

- Fintepla

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to fenfluramine.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescription must be written by a neurologist.
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## FYCOMPA

---

### Products Affected

- Fycompa oral suspension
- Fycompa oral tablet

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies tried, response to prior therapy
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be prescribed by neurologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Monitor at initiation and after dose increases for serious psychiatric and/or behavioral reactions.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## GALAFOLD

---

### Products Affected

- Galafold

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Not covered in combination with Fabrazyme
<b>Required Medical Information</b>	Confirmed diagnosis of Fabry disease and baseline renal function assessment
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by a specialist in genetic disorders, or nephrologist
<b>Coverage Duration</b>	6 months for initiation, 1 year for continuation
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## GATTEX

---

### Products Affected

- Gattex 30-Vial

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Therapy should be discontinued in cases of intestinal malignancy.
<b>Required Medical Information</b>	Diagnosis, other therapies tried and/or failed.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by a gastroenterologist
<b>Coverage Duration</b>	3 months for initiation, 6 months for continuation
<b>Other Criteria</b>	Under CMS Review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## GAUCHER'S DISEASE TREATMENT

---

### Products Affected

- Cerdelga
- miglustat
- Zavesca

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	NOT APPROVED FOR TYPE II OR TYPE III GAUCHER'S DISEASE
<b>Required Medical Information</b>	DIAGNOSIS, WEIGHT. FOR MIGLUSTAT: RATIONALE AS TO WHY ERT IS NOT APPROPRIATE
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY GENETICIST, HEMATOLOGIST, OR METABOLIC SPECIALIST
<b>Coverage Duration</b>	1 YEAR
<b>Other Criteria</b>	USE OF MIGLUSTAT IS RESERVED FOR THOSE WHOM ENZYME REPLACEMENT THERAPY IS NOT AN OPTION
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## GILOTRIF

---

### Products Affected

- Gilotrif

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, previous therapies tried and/or failed
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## GLEEVEC

---

### Products Affected

- imatinib oral tablet 100 mg, 400 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	DIAGNOSIS, PRIOR THERAPIES, AND TREATMENT RESPONSE
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	GENETIC, HEMATOLOGIC, AND CYTOGENIC TESTS ARE REQUIRED BASED ON THE SPECIFIC INDICATION TO ASSESS APPROPRIATE USE AND ADEQUATE RESPONSE TO THERAPY
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## GRALISE

---

### Products Affected

- Gralise
- Gralise 30-Day Starter Pack

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, previous treatments including dosage, outcome of previous treatment
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Must have a documented intolerance, contraindication to, or failure of gabapentin titrated to maximum tolerated dosage or rationale as to why gabapentin cannot be used.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## GROWTH HORMONE

---

### Products Affected

- Norditropin FlexPro
- Nutropin AQ Nuspin

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PRESENCE OF CONTRAINDICATIONS TO THERAPY
<b>Required Medical Information</b>	DIAGNOSIS, HEIGHT AND WEIGHT, HISTORY OF GROWTH MEASUREMENT. REPLACEMENT THERAPY IN PATIENTS WITH GROWTH HORMONE DEFICIENCY WITH DIAGNOSIS CONFIRMED BY APPROPRIATE GROWTH HORMONE STIMULATION TESTING
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY ENDOCRINOLOGIST OR NEPHROLOGIST
<b>Coverage Duration</b>	3 MONTHS FOR INITIATION, 1 YEAR FOR CONTINUATION
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## HEPATITIS B

---

### Products Affected

- Baraclude oral solution
- entecavir

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	TREATMENT CONSIDERATION IS BASED ON HBEAG, HBV DNA QUANTITY, AND ALT LEVEL
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY A GASTROENTEROLOGIST, HEPATOLOGIST, OR INFECTIOUS DISEASE SPECIALIST
<b>Coverage Duration</b>	1 YEAR
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## HEPATITIS C TREATMENT

---

### Products Affected

- Mavyret
- Zepatier

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	PATIENT WEIGHT, GENOTYPE, HCV-RNA , LEVEL OF FIBROSIS, TREATMENT HISTORY
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY GASTROENTEROLOGIST, HEPATOLOGIST, OR INFECTIOUS DISEASE SPECIALIST
<b>Coverage Duration</b>	8 - 24 WEEKS. TREATMENT WILL BE APPROVED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE.
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## HEREDITARY ANGIOEDEMA

---

### Products Affected

- Cinryze
- Haegarda
- icatibant
- Takhzyro

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, including the results immunologic laboratory testing that show low C4 (ie. less than 14 mg/dL, normal range 14 – 40 mg/dL) and functional C1- inhibitor levels (less than 50% or below lower limit of normal).
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by Allergist or Immunologist
<b>Coverage Duration</b>	3 months initially, 12 months for continuation
<b>Other Criteria</b>	Under CMS Review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## HETLIOZ

---

### Products Affected

- Hetlioz

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapies and responses.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescribed by a sleep specialist.
<b>Coverage Duration</b>	6 months for initiation, 1 year for continuation.
<b>Other Criteria</b>	Under CMS Review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

---

### Products Affected

- Juxtapid

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, results of prior therapy
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months for initiation, 6 months for continuation
<b>Other Criteria</b>	Patient must have a diagnosis of homozygous familial hypercholesterolemia. Liver function tests required at baseline and at least monthly during the first year of treatment.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## HUMIRA

### Products Affected

- Humira Pen
- Humira Pen Crohns-UC-HS Start
- Humira Pen Psor-Uveits-Adol HS
- Humira subcutaneous syringe kit 10 mg/0.2 mL, 20 mg/0.4 mL, 40 mg/0.8 mL
- Humira(CF) Pedi Crohns Starter subcutaneous syringe kit 80 mg/0.8 mL, 80 mg/0.8 mL-40 mg/0.4 mL
- Humira(CF) Pen Crohns-UC-HS
- Humira(CF) Pen Psor-Uv-Adol HS
- HUMIRA(CF) PEN SUBCUTANEOUS INJECTOR KIT 40 MG/0.4 ML
- Humira(CF) subcutaneous syringe kit 10 mg/0.1 mL, 20 mg/0.2 mL, 40 mg/0.4 mL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with another biologic DMARD or targeted synthetic DMARD.
<b>Required Medical Information</b>	Diagnosis, concurrent medications, previous therapies tried.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	RA/JIA/JRA/Ankylosing spondylitis, prescribed by or in consultation with rheumatologist. Psoriatic arthritis (PsA), prescribed by or in consultation with a rheumatologist or dermatologist. Plaque psoriasis (PP), prescribed by or in consultation with a dermatologist. UC/ CD, prescribed by or in consultation with a gastroenterologist. HS - dermatologist. UV-ophthalmologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	RA: patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic for RA are not required to 'step back' and try a conventional synthetic DMARD). JIA/JRA: patient has tried another a non-biologic DMARD (e.g., MTX, sulfasalazine, leflunomide, NSAID) - or - biologic DMARD (e.g., etanercept, abatacept, infliximab, anakinra, tocilizumab) or will be starting on adalimumab concurrently with MTX, sulfasalazine, or leflunomide. Approve without trying another agent if pt has absolute contraindication to MTX, sulfasalazine, or leflunomide or if pt has aggressive disease. PP: approve if the patient meets one of the following criteria: 1) pt has tried at least one traditional systemic agent (e.g., MTX,

<b>PA Criteria</b>	<b>Criteria Details</b>
	<p>cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (note: patients who have already tried a biologic for psoriasis are not required to 'step back' and try a traditional agent first) - OR - 2) patient has a contraindication to MTX as determined by the prescribing physician.</p> <p>CD: patient has tried corticosteroids (CSs), or if CSs are contraindicated, or if pt currently on CSs, or patient has tried one other agent for CD (e.g., azathioprine, 6-mercaptopurine, MTX, certolizumab, infliximab, ustekinumab, or vedolizumab) - OR - patient had ileocolonic resection or enterocutaneous (perianal or abdominal) or rectovaginal fistulas. UC: patient has tried a systemic therapy (e.g., 6-mercaptopurine, azathioprine, CSA, tacrolimus, infliximab, golimumab SC, or a corticosteroid such as prednisone or methylprednisolone) for 2 months or was intolerant to one of these agents, or the patient has pouchitis and has tried therapy with an antibiotic, probiotic, corticosteroid enema, or mesalamine (Rowasa) enema. HS: patient has tried ONE other therapy (e.g., intralesional or oral corticosteroids, systemic antibiotics, isotretinoin). Clinical criteria incorporated into the Humira 40 mg quantity limit edit allow for approval of additional quantities to accommodate induction dosing. The allowable quantity is dependent upon the induction dosing regimen for the applicable FDA-labeled indications as outlined in product labeling.</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## IBRANCE (S)

---

### Products Affected

- Ibrance

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## ICLUSIG

---

### Products Affected

- Iclusig

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist or hematologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Liver function monitoring required at baseline and 3 months after initiation
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## IDHIFA

---

### Products Affected

- Idhifa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, previous treatments, and outcome.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a hematologist/oncologist.
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## IMBRUVICA

---

### Products Affected

- Imbruvica oral capsule 140 mg, 70 mg
- Imbruvica oral tablet

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	DIAGNOSIS, PRIOR TREATMENTS, RESPONSE TO THERAPY
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be prescribed by oncologist, hematologist, or transplant specialist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## INBRIJA

### Products Affected

- Inbrija inhalation capsule, w/inhalation device

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to LEVODOPA ORAL INHALATION.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescription must be written by a neurologist.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Required trial and failure of: 1) both carbidopa/levodopa IR and ER and, 2) at least one other Parkinson's Disease drug: entacapone, pramipexole, ropinirole, selegiline, rasagiline, or amantadine. Intention to continue use of carbidopa/levodopa.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## INCRELEX

---

### Products Affected

- Increlex

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	DIAGNOSIS, HEIGHT AND WEIGHT MEASUREMENTS, GH LEVEL, IGF-1 LEVEL
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY ENDOCRINOLOGIST
<b>Coverage Duration</b>	3 MONTHS INITIAL, 1 YEAR CONTINUATION
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## INHALED TOBRAMYCIN

---

### Products Affected

- Tobi Podhaler inhalation capsule, w/inhalation device

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, therapies tried, and outcome
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by Infectious disease specialist or pulmonologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## INLYTA

---

### Products Affected

- Inlyta oral tablet 1 mg, 5 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	DIAGNOSIS, PRIOR TREATMENTS, RESPONSE TO THERAPY
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY A ONCOLOGIST
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

# INQOVI

---

## Products Affected

- Inqovi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to decitabine / cedazuridine
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescription must be written by a hematologist / oncologist.
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## INREBIC

---

### Products Affected

- Inrebic

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Evaluate baseline thiamine levels prior to treatment initiation, do not initiate fedratinib in patients with thiamine deficiency. Replete thiamine prior to fedratinib initiation and during treatment if thiamine levels are low.
<b>Required Medical Information</b>	Diagnosis, Other therapies tried with treatment response, baseline thiamine level, baseline platelet level
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by Hematologist / Oncologist
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	Documented baseline platelet count of at least 50,000 per cubic millimeter.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## INTERFERON ALPHA

### Products Affected

- Intron A injection
- Pegasys ProClick subcutaneous pen injector 180 mcg/0.5 mL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	FOR HEPATITIS C: PATIENT WEIGHT, GENOTYPE, HCV-RNA QUANTITY AND DATE OF TEST, PRESENCE OF CIRRHOSIS (Y/N), TREATMENT HISTORY, HISTORY OF ANEMIA OR DEPRESSION. HEPATITIS B: HBEAG STATUS, HBV DNA QUANTITY, AND ALT LEVEL. OTHERS: DIAGNOSIS, OTHER THERAPIES TRIED AND FAILED, RESPONSE TO TREATMENT
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	2 YEARS FOR INDICATIONS OTHER THAN HEPATITIS C. HEPC APPROVALS FROM 12-48 WKS BASED ON DRUG REGIMEN
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## IRESSA

---

### Products Affected

- Iressa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, response to prior therapy
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	GEFITINIB IS COVERED AS MONOTHERAPY
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## IVIG

### Products Affected

- Bivigam
- Flebogamma DIF
- Gammagard Liquid
- Gammagard S-D (IgA < 1 mcg/mL)
- Gammaked injection solution 1 gram/10 mL (10 %), 10 gram/100 mL (10 %), 20 gram/200 mL (10 %), 5 gram/50 mL (10 %)
- Gammaplex
- Gammaplex (with sorbitol)
- Gamunex-C
- Octagam
- Privigen

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies tried and response to treatments.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	Diagnosis and administration information will be reviewed to determine if coverage is available as a Medicare Part B or Part D benefit. SCIG will be reserved for members who cannot use IVIG due to poor access (on going access site issues unresolved by traditional means) or SCIG will be reserved for patients who continue to experience infusion reactions despite documented infusion rate adjustments and adequate pre-treatment. For Idiopathic thrombocytopenia purpura (ITP): trial and failure of oral corticosteroids at therapeutic dose (standard dosage of prednisone is 1 mg/kg/day) required. For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): trial and failure of oral corticosteroids at therapeutic dose (standard dosage of prednisone is 1–1.5 mg/kg/day) required.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## JAKAFI

---

### Products Affected

- Jakafi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	DIAGNOSIS, OTHER TREATMENTS TRIED AND FAILED, CBC AT BASELINE AND PERIODICALLY AFTER INITIATION, HISTORY OF RBC TRANSFUSIONS
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIBER MUST BE A HEMATOLOGIST OR ONCOLOGIST
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Under CMS Review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## JYNARQUE

---

### Products Affected

- Jynarque oral tablets, sequential 45 mg (AM)/ 15 mg (PM), 60 mg (AM)/ 30 mg (PM), 90 mg (AM)/ 30 mg (PM)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	History of signs or symptoms of significant liver impairment or injury
<b>Required Medical Information</b>	Documented diagnosis of polycystic kidney disease, ultrasound results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by endocrinology or nephrology
<b>Coverage Duration</b>	6 months initial, 1 year continuation
<b>Other Criteria</b>	Under CMS Review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## KALYDECO

---

### Products Affected

- Kalydeco oral granules in packet
- Kalydeco oral tablet

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis and the presence of one or more specific gene mutations that the drug is FDA approved to treat.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months initially, 12 months for continuation
<b>Other Criteria</b>	Under CMS Review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## KINERET

---

### Products Affected

- Kineret

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies tried and/or failed
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by rheumatologist or pediatrician
<b>Coverage Duration</b>	3 months initially, 6 months for continuation
<b>Other Criteria</b>	Under CMS Review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## KISQALI

---

### Products Affected

- Kisqali
- Kisqali Femara Co-Pack

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies previously tried, and the outcome.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## KORLYM

---

### Products Affected

- Korlym

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies tried and outcome, HbA1c
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by endocrinologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Must have trial of ketoconazole or metyrapone therapy or have intolerance or contraindication to these medications. Must have failed surgery or not be a candidate for surgery. For continuation of therapy patient must show an improvement in HbA1c.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## KUVAN

---

### Products Affected

- Kuvan oral powder in packet 100 mg
- Kuvan oral tablet, soluble

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	DIAGNOSIS AND BASELINE AND FOLLOW UP PHENYLALANINE LEVELS. FOR CONTINUATION, MUST SHOW A 30% REDUCTION IN PHE LEVELS FROM BASELINE
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	2 MONTHS FOR INITIATION, 1 YEAR FOR CONTINUATION
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## LENVIMA

---

### Products Affected

- Lenvima

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## LEUKINE

---

### Products Affected

- Leukine injection recon soln

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	DIAGNOSIS
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## LIBTAYO

---

### Products Affected

- Libtayo

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies tried and/or failed, and response to prior therapy
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by or in consultation with an oncologist or hematologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## LIDOCAINE TRANSDERMAL

---

### Products Affected

- lidocaine topical adhesive patch,medicated 5 %
- lidocaine topical ointment

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## LOKELMA

---

### Products Affected

- Lokelma

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of hyperkalemia, confirmed with laboratory test within the past month.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	6 months for initiation, 1 year for continuation
<b>Other Criteria</b>	For initiation, must have a failure, contraindication, or intolerance to sodium polystyrene sulfonate. For continuation, must show response to therapy as demonstrated by normal potassium levels and patient remains at high risk for recurrence of hyperkalemia.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## LONSURF

---

### Products Affected

- Lonsurf

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies tried and/or failed, and treatment response
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## LORBRENA

---

### Products Affected

- Lorbrena

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to treatment.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## LYNPARZA

---

### Products Affected

- Lynparza oral tablet

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	DIAGNOSIS, PRIOR THERAPIES, GENETIC TESTING
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST
<b>Coverage Duration</b>	3 months initiation, 6 months continuation
<b>Other Criteria</b>	Under CMS Review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## MAVENCLAD

### Products Affected

- Mavenclad (10 tablet pack)
- Mavenclad (4 tablet pack)
- Mavenclad (5 tablet pack)
- Mavenclad (6 tablet pack)
- Mavenclad (7 tablet pack)
- Mavenclad (8 tablet pack)
- Mavenclad (9 tablet pack)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Excluded for patients with HIV, active chronic hepatitis, or tuberculosis.
<b>Required Medical Information</b>	For MS Diagnosis, EDSS score, relapse history, physical or cognitive disability, TB test
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by a neurologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	For MS-failure of at least two of the following: glatiramer or glatopa AND either Gilenya, Betaseron, or Avonex.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## MAYZENT

---

### Products Affected

- Mayzent

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, EDSS score, relapse history, and physical or cognitive disability
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by a neurologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Failure of at least two of the following: glatiramer or glatopa AND either Gilenya, Betaseron, or Avonex.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## MEDICALLY ACCEPTED USE

---

### Products Affected

- topiramate oral capsule, sprinkle
- topiramate oral tablet
- zonisamide

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## MEKINIST

---

### Products Affected

- Mekinist oral tablet 0.5 mg, 2 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Wild-type BRAF melanoma
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. Documentation of BRAF mutation, as detected using an FDA-approved test.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## MEKTOVI

---

### Products Affected

- Mektovi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to treatment.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Must be used in combination with encorafenib.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## METHAMPHETAMINE

---

### Products Affected

- methamphetamine

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies previously tried and failed, and response to treatment
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	For the treatment of attention deficit disorder patient must have a trial of both methylphenidate and amphetamine/dextroamphetamine or rationale as to why these treatments are not suitable.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## MIRVASO

---

### Products Affected

- Mirvaso topical gel with pump

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis and other treatments tried and outcome.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	For the treatment of acne rosacea: doxycycline (oral) and topical metronidazole.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## MULPLETA

---

### Products Affected

- Mulpleta

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis and platelet count
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Must be prescribed by a hematologist, oncologist, or gastroenterologist
<b>Coverage Duration</b>	1 month
<b>Other Criteria</b>	Patient must be scheduled to undergo a pre-planned medical or dental procedure with treatment beginning 8 to 14 days prior to the scheduled procedure. Patients should undergo their procedure 2 to 8 days after the last dose.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## MULTIPLE SCLEROSIS

### Products Affected

- Aubagio
- Avonex intramuscular pen injector kit
- Avonex intramuscular syringe kit
- Betaseron subcutaneous kit
- Gilenya oral capsule 0.5 mg
- glatiramer
- Glatopa
- Plegridy
- Tecfidera

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, EDSS score, relapse history, and physical or cognitive disability
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by a neurologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Patient must have a trial of or contraindication to glatiramer or glatopa prior to initiating the other drugs listed in this criteria.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## MU-OPIOID RECEPTOR ANTAGONIST.

---

### Products Affected

- Movantik
- Symproic

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Will not be approved for cancer related pain
<b>Required Medical Information</b>	Documented diagnosis of opiate induced constipation (non-cancer pain)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Patient must have a trial of or contraindication to at least two different classes of laxative agents including bulk, osmotic, or stimulant laxatives.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## MYALEPT

---

### Products Affected

- Myalept

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months for initiation, 1 year for continuation
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## NATPARA

---

### Products Affected

- Natpara

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	DIAGNOSIS, BASELINE SERUM CALCIUM AND 25-HYDROXYVITAMIN D LEVELS
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	MUST BE PRESCRIBED BY AN ENDOCRINOLOGIST
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## NAYZILAM

---

### Products Affected

- Nayzilam

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to midazolam.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by a neurologist.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## NERLYNX

---

### Products Affected

- Nerlynx

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, previous treatments, and outcome.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Under CMS Review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## NEUPRO

---

### Products Affected

- Neupro

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies tried and/or failed, frequency of symptoms
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Patient must have a trial of or contraindication to two of the following therapies prior to coverage of Neupro: pramipexole, ropinirole, or carbidopa/levodopa.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## NEXAVAR

---

### Products Affected

- Nexavar

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	DIAGNOSIS, PRIOR THERAPIES, AND TREATMENT RESPONSE
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## NINLARO

---

### Products Affected

- Ninlaro

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies tried and/or failed, and treatment response. Used in combination with Revlimid (lenalidomide) and dexamethasone.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist or hematologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Must have an intolerance or contraindication to Velcade
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## NOXAFIL

---

### Products Affected

- Noxafil oral suspension

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, therapies tried, and outcome
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed Infectious disease specialist
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	For the treatment of aspergillosis patient must have failure of, intolerance or contraindication to voriconazole OR rationale as to why voriconazole is not suitable.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## NUBEQA

---

### Products Affected

- Nubeqa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to darolutamide.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist or urologist.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## NUCALA

---

### Products Affected

- Nucala

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	For patients with asthma: allergen test, baseline FEV1, FEV1 following bronchodilator, asthma medical history (including medications, emergency department visits, and hospitalizations), baseline eosinophil count. For patients with eosinophilic granulomatosis with polyangiitis: documentation of diagnosis, prior therapies, and the outcome.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Pulmonologist, immunologist, allergist or rheumatologist.
<b>Coverage Duration</b>	3 months for initial, 1 year for continuation
<b>Other Criteria</b>	For patients with asthma: must be currently receiving inhaled and/or oral corticosteroid treatment, AND have a baseline eosinophil count of 300 cells/mcL or greater within previous 12 months or 150 cell/mcL within previous 6 weeks.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## NUEDEXTA

---

### Products Affected

- Nuedexta

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescription must be written by or in consultation with a neurologist, psychiatrist or geriatrician.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## NUPLAZID

---

### Products Affected

- Nuplazid oral capsule
- Nuplazid oral tablet 10 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Parkinson's disease psychosis: Diagnosis of Parkinson's disease. Patient has at least one of the following: hallucinations or delusions.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by or in consultation with a neurologist or psychiatrist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## NURTEC

---

### Products Affected

- Nurtec ODT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Excluded for migraine prevention.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Under CMS Review.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Unless contraindicated per the FDA label, a trial of at least one-month of two different triptans: one oral tablet and one other formulation, either nasal spray or injection.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## OCALIVA

---

### Products Affected

- Ocaliva

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies tried and failed, and response to therapy, baseline alkaline phosphatase (ALP) level for initiation, and ALP levels after first 3 months of therapy and then yearly for continuation of therapy.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months for initial and 1 year for continuation
<b>Other Criteria</b>	Use in combination with ursodiol in patients with an inadequate biochemical response to treatment (elevated ALP levels) with ursodiol dosed at 13-15 mg/kg/day for at least 1 year, may be used as monotherapy in patients unable to tolerate ursodiol. Must show improvement in ALP levels for continuation.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## ODOMZO

---

### Products Affected

- Odomzo

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Patient has recurring disease following surgery or radiation OR patient is not a candidate for surgery or radiation therapy
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist or dermatologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## ORENCIA

### Products Affected

- Orencia ClickJect
- Orencia subcutaneous syringe 125 mg/mL, 50 mg/0.4 mL, 87.5 mg/0.7 mL

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, other treatments tried and reasons for failure. Regular monitoring for TB required, both at baseline and during treatment.
Age Restrictions	Beneficiary is of appropriate age for use per FDA prescribing information.
Prescriber Restrictions	PRESCRIPTION MUST BE WRITTEN BY A RHEUMATOLOGIST
Coverage Duration	1 year
Other Criteria	For arthritic conditions, an adequate trial at least one non-biologic DMARD (methotrexate, hydroxychloroquine, sulfasalazine, azathioprine) and documented reason for failure (or contraindication).
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

## ORFADIN

### Products Affected

- nitisinone
- Orfadin oral capsule 20 mg
- Orfadin oral suspension

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	DIAGNOSIS AND WEIGHT
Age Restrictions	N/A
Prescriber Restrictions	PRESCRIPTION MUST BE WRITTEN BY AN ENDOCRINOLOGIST, GASTROENTEROLOGIST, HEMATOLOGIST, METABOLIC SPECIALIST, OR NEPHROLOGIST
Coverage Duration	3 MONTHS INITIAL, 1 YEAR CONTINUATION
Other Criteria	CLOSE MONITORING OF DISEASE MARKERS (ERYTHROCYTE PBG-SYNTHASE ACTIVITY, URINE 5-ALA, SUCCINYLACETONE) DURING THE FIRST 3 MONTHS OF TREATMENT TO ENSURE NORMALIZATION
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

## ORKAMBI

---

### Products Affected

- Orkambi oral granules in packet
- Orkambi oral tablet

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Patient has a diagnosis of cystic fibrosis (CF) AND Patient is homozygous for the F508del mutation in the CF transmembrane conductance regulator (CFTR) gene AND The presence of the mutation was documented by an FDA-cleared cystic fibrosis mutation test.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	For renewal, Patient is benefiting from treatment (i.e., improvement in lung function [forced expiratory volume in one second [FEV1], decreased number of pulmonary exacerbations)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## ORLISSA

---

### Products Affected

- Orilissa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapies, and result of prior therapy.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Must have a failure, contraindication, or intolerance to a continuous hormonal contraceptive AND progestin therapy (e.g. medroxyprogesterone, norethindrone).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## OTEZLA

### Products Affected

- Otezla
- Otezla Starter oral tablets, dose pack 10 mg (4)-20 mg (4)-30 mg (4)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapy used, result of prior therapy
Age Restrictions	N/A
Prescriber Restrictions	Must be prescribed by a Rheumatologist or Dermatologist
Coverage Duration	3 months for initiation, 2 years for continuation
Other Criteria	For arthritis conditions, must have a trial of or contraindication to one non-biologic DMARD (including but not limited to methotrexate, hydroxychloroquine, sulfasalazine, azathioprine). For diagnosis of plaque psoriasis, must have a trial of or contraindication to cyclosporine or methotrexate
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

## OXERVATE

---

### Products Affected

- Oxervate

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapies, and result of prior therapy.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an ophthalmologist
<b>Coverage Duration</b>	8 weeks
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## PALYNZIQ

---

### Products Affected

- Palynziq

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior treatments, and outcome. Baseline and follow up phenylalanine (Phe) concentrations.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months for initial, 1 year for continuation
<b>Other Criteria</b>	Must have phenylalanine (Phe) concentrations greater than 600 micromol/L on existing management, and a failure, contraindication, or intolerance to Kuvan.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## PDE-5 INHIBITORS FOR PAH

### Products Affected

- Alyq
- sildenafil (Pulmonary Arterial Hypertension) oral suspension for reconstitution 10 mg/mL
- sildenafil (Pulmonary Arterial Hypertension) oral tablet 20 mg
- tadalafil (pulmonary arterial hypertension) oral tablet 20 mg

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, right heart cath results.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	For PAH: prescribed by, or in consultation with, a cardiologist or a pulmonologist.
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Pulmonary arterial hypertension (PAH) WHO Group 1, are required to have had a right-heart catheterization to confirm diagnosis of PAH to ensure appropriate medical assessment. Sildenafil must be tried prior to the use of the other drugs included in these criteria, unless using ambrisentan (Letairis) plus tadalafil for treatment-naïve, WHO functional class II or III PAH.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## PEMAZYRE

---

### Products Affected

- Pemazyre

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to pemigatinib.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist or gastroenterologist.
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Documentation of a susceptible fibroblast growth factor receptor 2 fusion or other genetic rearrangement (as detected by an FDA-approved test).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## PIQRAY

### Products Affected

- Piqray

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapies
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 years
Other Criteria	Breast Cancer. Approve if the patient meets the following criteria (A, B, C, D, and E): A) The patient is a postmenopausal female or a male AND B) The patient has advanced or metastatic hormone receptor (HR)-positive disease AND C) The patient has human epidermal growth factor receptor 2 (HER2)-negative disease AND D) The patient has PIK3CA-mutated breast cancer as detected by an approved test AND E) The patient has progressed on or after at least one prior endocrine-based regimen (e.g., anastrozole, letrozole, exemestane, Faslodex, tamoxifen, toremifene).
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

## POMALYST

---

### Products Affected

- Pomalyst

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist or hematologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## PROLIA

---

### Products Affected

- Prolia

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Under CMS Review.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed or in consultation with Endocrinologist, Hematologist/Oncologist, Obstetrician/Gynecologist, Rheumatologist or Urologist
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	Under CMS Review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## PROMACTA

---

### Products Affected

- Promacta

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	For ITP, eltrombopag should only be used if the degree of thrombocytopenia and clinical condition increase the risk for bleeding. For chronic hepatitis C, eltrombopag should only be used if the degree of thrombocytopenia prevents initiation of or limits the ability to maintain interferon-based therapy. Eltrombopag is not indicated for the treatment of myelodysplastic syndromes.
<b>Required Medical Information</b>	Diagnosis, other therapies tried and outcome. Platelet count.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## PULMONARY FIBROSIS

---

### Products Affected

- Esbriet oral capsule
- Esbriet oral tablet 267 mg, 801 mg
- Ofev

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	liver function
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	prescriber must be a pulmonologist.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## PULMONARY HYPERTENSION

---

### Products Affected

- ambrisentan
- bosentan
- Opsumit
- Orenitram
- Tracleer oral tablet for suspension
- Tyvaso
- Tyvaso Institutional Start Kit
- Tyvaso Refill Kit
- Tyvaso Starter Kit
- Ventavis

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Confirmation of diagnosis of pulmonary arterial hypertension (WHO GROUP 1). Prior therapies used and responses to treatments.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by a pulmonologist or cardiologist.
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Under CMS Review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## PURIXAN

---

### Products Affected

- Purixan

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	DIAGNOSIS, PRIOR TREATMENTS, RESPONSE TO THERAPY
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	prescriber must be a oncologist or hematologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## QINLOCK

---

### Products Affected

- Qinlock

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to ripretinib.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescription must be written by a oncologist or gastroenterologist.
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	For initiation, documentation of prior treatment with three or more kinase inhibitors, including imatinib.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## REPATHA

### Products Affected

- Repatha
- Repatha Pushtronex
- Repatha SureClick

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use of Juxtapid or Praluent.
<b>Required Medical Information</b>	LDL-C and response to other agents, prior therapies tried, medication adverse event history, medical history
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescribed by, or in consultation with, a cardiologist, endocrinologist, or a physician who focuses in the treatment of CV risk management and/or lipid disorders
<b>Coverage Duration</b>	Approve for 3 years for ASCVD/HeFH/HoFH. Approve for 1 year for primary hyperlipidemia.
<b>Other Criteria</b>	Hyperlipidemia with HeFH - approve if: (1) diagnosis of HeFH - AND - (2) tried ezetimibe and ONE high intensity statin (e.g., atorvastatin greater than or equal to 40 mg daily or rosuvastatin greater than or equal to 20 mg daily) and LDL remains 70 mg/dL or higher, unless patient is statin intolerant defined by experiencing statin-related rhabdomyolysis or skeletal-related muscle symptoms while receiving separate trials of atorvastatin and rosuvastatin, and during both trials the symptoms resolved upon discontinuation. For hyperlipidemia with ASCVD, approve if: (1) has one of the following conditions: prior MI, h/o ACS, diagnosis of angina, h/o CVA or TIA, PAD, undergone a coronary or other arterial revascularization procedure - AND - (2) tried ezetimibe and ONE high intensity statin (defined above) and LDL remains 70 mg/dL or higher, unless patient is statin intolerant (defined above). For HoFH, approve if: (1) has one of the following: (a) genetic confirmation of two mutant alleles at the LDLR, APOB, PCSK9, or LDLRAP1 gene locus, OR (b) untreated LDL greater than 500 mg/dL (prior to treatment), OR (c) treated LDL greater than or equal to 300 mg/dL (after treatment but prior to agents such as Repatha or Juxtapid), OR (d) has clinical manifestations of HoFH (e.g., cutaneous xanthomas, tendon xanthomas, arcus cornea, tuberous xanthomas or xanthelasma), AND - (2) tried ezetimibe and ONE high

Prior Authorization Criteria  
 Health Alliance Plan 2021  
 Date Effective: 01/01/2021

<b>PA Criteria</b>	<b>Criteria Details</b>
	intensity statin (defined above) for 8 weeks or longer and LDL remains 70 mg/dL or higher unless statin intolerant (defined above). For primary hyperlipidemia with LDL of 190 or higher (not associated with ASCVD, HeFH, or HoFH), approve if tried one high-intensity statin therapy (defined above) and ezetimibe for at least 8 weeks and LDL remains 100 mg/dL or higher, unless statin intolerant (defined above).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## RETEVMO

---

### Products Affected

- Retevmo

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to selpercatinib.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescription must be written by a oncologist, pulmonologist or endocrinologist.
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	For initiation, documentation of the presence of a RET gene fusion (with non-small cell lung cancer or thyroid cancer) or specific RET gene mutation (medullary thyroid cancer) in tumor specimens or plasma.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## REVCovi

---

### Products Affected

- Revcovi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documented diagnosis of Adenosine deaminase (ADA) deficiency, IgA, IgM, and IgG levels, CBC, and presence of mutations in the ADA gene at 20q13.11
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by immunologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## REVLIMID

---

### Products Affected

- Revlimid

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis and previous therapies or drug regimens tried.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 years
Other Criteria	MCL-approve if the patient meets one of the following 1) Pt has tried two prior therapies or therapeutic regimens OR 2) Pt has tried one prior therapy or therapeutic regimen and cannot take Velcade according to the prescribing physician. MDS-approve if the patient meets one of the following: 1) Pt has symptomatic anemia, OR 2) Pt has transfusion-dependent anemia, OR 3) Pt has anemia that is not controlled with an erythroid stimulating agent (eg, Epogen, Procrit [epoetin alfa injection], Aranesp [darbepoetin alfa injection]). Diffuse, Large B Cell Lymphoma (Non-Hodgkin's Lymphoma)-approve if the pt has tried one other medication treatment regimen. Myelofibrosis-approve if the pt has tried one other therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

## REYVOW

---

### Products Affected

- Reyvow

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Excluded for migraine prevention.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Under CMS Review.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Unless contraindicated per the FDA label, a trial of at least one-month of two different triptans: one oral tablet and one other formulation, either nasal spray or injection.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## RINVOQ

---

### Products Affected

- Rinvoq

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to UPADACITINIB.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by a rheumatologist.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Documented trial and failure of triple therapy with oral non-biologic DMARDs, a combination of methotrexate, hydroxychloroquine and sulfasalazine, for at least three months or a contraindication to triple therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## ROZLYTREK

---

### Products Affected

- Rozlytrek oral capsule 100 mg, 200 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to ENTRECTINIB.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## RUBRACA

---

### Products Affected

- Rubraca

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Under CMS Review.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## RYDAPT

### Products Affected

- Rydapt

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Acute Myeloid Leukemia (AML): Newly diagnosed acute myeloid leukemia (AML), FMS-like tyrosine kinase 3 (FLT3) mutation-positive as detected by a U.S. Food and Drug Administration (FDA)-approved test, used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. Aggressive Systemic Mastocytosis (ASM), Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN), Mast Cell Leukemia (MCL): Diagnosis of one of the following: aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	All indications: Prescribed by or in consultation with a hematologist or oncologist.
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Approve for continuation of prior therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## SAMSCA

---

### Products Affected

- Samsca oral tablet 15 mg
- tolvaptan oral tablet 30 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, patient has a serum sodium less than 125 mEq/L at baseline, OR member has less marked hyponatremia (serum sodium less than 135 mEq/L at baseline) AND is symptomatic (e.g. nausea, vomiting, headache, lethargy, confusion, and baseline LFTs)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by endocrinology or nephrology
<b>Coverage Duration</b>	1 month
<b>Other Criteria</b>	Patient must have documented failure of two other therapies (e.g. fluid restriction, furosemide, demeclocycline).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## SAVELLA

---

### Products Affected

- Savella oral tablet
- Savella oral tablets,dose pack

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	DIAGNOSIS OF FIBROMYALGIA, RESPONSE TO THERAPY
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 YEAR
<b>Other Criteria</b>	MUST HAVE TREATMENT FAILURE, INTOLERANCE, OR CONTRAINDICATION TO MAXIMALLY TOLERATED GABAPENTIN AND DULOXETINE.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## SENSIPAR

---

### Products Affected

- cinacalcet oral tablet 30 mg, 60 mg, 90 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior treatments and responses.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	For secondary hyperparathyroidism associated with CKD undergoing dialysis, trial and failure with ONE phosphate binder (e.g. calcium acetate, sevelamer) - AND - ONE vitamin D analog (e.g. doxercalciferol, calcitriol, paricalcitol).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## SIGNIFOR

---

### Products Affected

- Signifor

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis and other treatments tried and failed. Documentation: of surgery with response (if performed), or when surgery is not a treatment option.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an endocrinologist
<b>Coverage Duration</b>	3 months for initiation, 6 months for continuation.
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## SIRTURO

---

### Products Affected

- Sirturo

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies tried and/or failed. ECG and liver function tests are required at baseline and at intervals as specified in the FDA prescribing information to monitor for potentially severe adverse events.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by a infectious disease specialist
<b>Coverage Duration</b>	24 weeks
<b>Other Criteria</b>	Drug therapy must be directly observed. Use of Sirturo is reserved for MDR-TB where other treatment options cannot be used for safety or efficacy reasons.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## SKYRIZI

---

### Products Affected

- Skyrizi subcutaneous syringe kit

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Must be prescribed by a Dermatologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	For diagnosis of plaque psoriasis, must have a trial of or contraindication to cyclosporine or methotrexate
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## SPRITAM

---

### Products Affected

- Spritam

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, therapies tried, and outcome
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by Neurologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Rationale as to why generic levetiracetam is not suitable.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## SPRYCEL

---

### Products Affected

- Sprycel

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Must have a failure, intolerance or contraindication to imatinib.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## STELARA

### Products Affected

- Stelara subcutaneous solution
- Stelara subcutaneous syringe 45 mg/0.5 mL, 90 mg/mL

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapies, and result of prior therapy. TB test results
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by gastroenterologist, dermatologist or rheumatologist.
Coverage Duration	1 year
Other Criteria	For arthritis conditions, must have a trial of or contraindication to one non-biologic DMARD (including but not limited to methotrexate, hydroxychloroquine, sulfasalazine, azathioprine). For diagnosis of plaque psoriasis, must have a trial of or contraindication to cyclosporine or methotrexate. For Crohn's disease, must have trial of or contraindication to at least one non-biologic conventional therapy, including but not limited to sulfasalazine, mesalamine, azathioprine, or methotrexate.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

## STIVARGA

---

### Products Affected

- Stivarga

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to regorafenib. LFT lab test results are needed for continuation treatment.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## SUTENT

---

### Products Affected

- Sutent

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	DIAGNOSIS, PRIOR THERAPIES, AND TREATMENT RESPONSE. DOCUMENTATION OF FAILURE OF IMATINIB FOR PATIENTS WITH GIST. DOCUMENTATION OF FAILURE OF VOTRIENT FOR PATIENTS WITH RENAL CELL CARCINOMA. IF NO PREVIOUS FAILURE, RATIONALE AS TO WHY PREFERRED AGENT CANNOT BE USED
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	GIST PATIENTS REQUIRE A FOLLOW-UP CT SCAN BETWEEN 8 AND 12 WEEKS.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## SYLATRON

### Products Affected

- PegIntron subcutaneous kit 50 mcg/0.5 mL
- Sylatron subcutaneous kit 200 mcg, 300 mcg

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	HISTORY OF HEPATITIS OR HEPATIC DECOMPENSATION
<b>Required Medical Information</b>	DIAGNOSIS OF MALIGNANT MELANOMA WITH EVIDENCE OF NODAL INVOLVEMENT
<b>Age Restrictions</b>	18 YEARS AND OLDER
<b>Prescriber Restrictions</b>	PRESCRIBER MUST BE ONCOLOGIST OR DERMATOLOGIST
<b>Coverage Duration</b>	6 MONTHS
<b>Other Criteria</b>	MONITOR FOR NEUROPSYCHIATRIC DISORDERS, TOXICITY, AND NEW OR WORSENING RETINOPATHY
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## SYMDEKO

---

### Products Affected

- Symdeko

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis of CF AND homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence. If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. FEV1 at baseline and continuation, baseline LFT and continuation, review for drug interactions CYP3A inducers
Age Restrictions	N/A
Prescriber Restrictions	Must be prescribed by a pulmonologist or doctor specializing in cystic fibrosis
Coverage Duration	6 months initial, 1 year continuation
Other Criteria	For renewal, Patient is benefiting from treatment (i.e., improvement in lung function [forced expiratory volume in one second (FEV1)], decreased number of pulmonary exacerbations)
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

## SYMLIN

---

### Products Affected

- SymlinPen 120
- SymlinPen 60

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	GASTROPARESIS OR USE OF DRUGS TO STIMULATE GASTROINTESTINAL MOTILITY
<b>Required Medical Information</b>	HBA1C AND CURRENT DIABETES MEDICATIONS
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 YEAR
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## SYMPAZAN

---

### Products Affected

- Sympazan oral film 10 mg, 20 mg, 5 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Must have failure, intolerance, or contraindication to generic clobazam
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## SYNRIBO

---

### Products Affected

- Synribo

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist or hematologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## TABRECTA

---

### Products Affected

- Tabrecta

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to capmatinib.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescribed by an oncologist or pulmonologist.
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Documentation of a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## TAFAMIDIS

---

### Products Affected

- Vyndamax
- Vyndaqel

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Confirmation of diagnosis with appropriate testing.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by a cardiologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## TAFINLAR

---

### Products Affected

- Tafinlar

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Wild-type BRAF melanoma
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. Documentation of BRAF mutation, as detected using an FDA-approved test.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## TAGRISO

---

### Products Affected

- Tagrisso

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis supported with an approved test for the detection of mutations named in FDA label found in tumor or plasma specimens. Other therapies tried and responses to treatments.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by an oncologist.
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## TALZENNA

---

### Products Affected

- Talzenna

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to treatment.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## TARCEVA

---

### Products Affected

- erlotinib

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	DIAGNOSIS, PRIOR THERAPIES, AND TREATMENT RESPONSE
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## TARGRETIN

---

### Products Affected

- Targretin topical

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, response to bexarotene.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescribing limited to a specialist in hematology/oncology.
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	Documentation that the patient has refractory or persistent cutaneous T-cell lymphoma (stage IA and IB) or who has not tolerated other therapies
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## TASIGNA

---

### Products Affected

- Tasigna oral capsule 150 mg, 200 mg, 50 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	DIAGNOSIS, OTHER THERAPIES TRIED AND FAILED, RESPONSE TO TREATMENT, POTENTIAL DRUG INTERACTIONS
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY AN ONCOLOGIST
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Must have a failure, intolerance or contraindication to imatinib and Sprycel.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## TAVALISSE

---

### Products Affected

- Tavalisse

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies tried, outcome, and platelet count less than 50,000/microL for at least 3 months
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Must be prescribed by a hematologist or oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Patient must have a failure, contraindication, or intolerance to at least two of the following therapies: corticosteroids, IVIG, Rituxan, or Promacta. For continuation of therapy the platelet counts must be to a level sufficient to avoid clinically important bleeding.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## TAZORAC

---

### Products Affected

- tazarotene
- Tazarac topical cream 0.05 %
- Tazorac topical gel

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	DIAGNOSIS, OTHER THERAPIES TRIED AND FAILED.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 YEAR
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## TAZVERIK

---

### Products Affected

- Tazverik

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to tazemetostat.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescribing limited to a hematologist/oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## TEGSEDI

---

### Products Affected

- Tegsedi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR). For continuation of therapy, demonstrated positive response to therapy (improved neurologic impairment, motor function, or slowing of disease progression)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Must be prescribed by a geneticist or neurologist
<b>Coverage Duration</b>	6 months for initiation, 1 year for continuation
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## TESTOSTERONE

### Products Affected

- testosterone transdermal gel in metered-dose pump 12.5 mg/ 1.25 gram (1 %), 20.25 mg/1.25 gram (1.62 %)
- testosterone transdermal gel in packet

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of primary hypogonadism (congenital or acquired) in males. Diagnosis of secondary (hypogonadotropic) hypogonadism (congenital or acquired) in males. Hypogonadism (primary or secondary) in males, serum testosterone level. [Man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression.]
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Hypogonadism (primary or secondary) in males - initial therapy, approve if all of the following criteria are met: 1) patient has persistent signs and symptoms of androgen deficiency (pre-treatment) [eg, depressed mood, decreased energy, progressive decrease in muscle mass, osteoporosis, loss of libido, AND 2) patient has had two pre-treatment serum testosterone (total or available) measurements, each taken in the morning on two separate days, AND 3) the two serum testosterone levels are both low, as defined by the normal laboratory reference values. hypogonadism has been confirmed by a low for age serum testosterone (total or free) level defined by the normal laboratory reference values. Hypogonadism (primary or secondary) in males - continuing therapy, approve if the patient meets all of the following criteria: 1) patient has persistent signs and symptoms of androgen deficiency (pre-treatment) AND 2) patient had at least one pre-treatment serum testosterone level that was low. [Note: male is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression.]

Prior Authorization Criteria  
Health Alliance Plan 2021  
Date Effective: 01/01/2021

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## TIBSOVO

---

### Products Affected

- Tibsovo

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to treatment.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## TRANSMUCOSAL IMMEDIATE RELEASE FENTANYL

---

### Products Affected

- fentanyl citrate buccal lozenge on a handle

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	NOT APPROVED FOR PATIENTS WHO ARE NOT TOLERANT TO OPIOID THERAPY AND ARE NOT RECEIVING LONG ACTING OPIATE THERAPY
<b>Required Medical Information</b>	Diagnosis and trial of two formulary short-acting opioid analgesics such as oxycodone, morphine, or hydromorphone as immediate-release (IR) tablet formulations or oral solution.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	DOCUMENTATION AS TO WHY A UNIQUE METHOD OF ADMINISTRATION IS NEEDED AND A TRADITIONAL SHORT ACTING ORAL OPIATE MEDICATION IS NOT SUITABLE. PRIOR TO COVERAGE, THE PLAN WILL DETERMINE WHETHER THE DIAGNOSIS MEETS PART D REQUIREMENTS FOR APPROVAL.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## TRELSTAR DEPOT, TRELSTAR LA

---

### Products Affected

- Trelstar intramuscular suspension for reconstitution

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	DIAGNOSIS
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY AN ONCOLOGIST.
<b>Coverage Duration</b>	6 MONTHS AT A TIME
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## TRETINOIN

---

### Products Affected

- Avita topical cream
- Avita topical gel
- tretinoin topical

PA Criteria	Criteria Details
Exclusion Criteria	Coverage is not provided for cosmetic use.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

## TRIENTINE

---

### Products Affected

- Clovique
- trientine

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies tried and the outcome, ferritin, LFTs baseline, serum iron, hemoglobin, and hematocrit
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a gastroenterologist.
<b>Coverage Duration</b>	3 months for initiation, 6 months for continuation
<b>Other Criteria</b>	Must have a failure, contraindication, or intolerance to penicillamine.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## TUKYSA

---

### Products Affected

- Tukysa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to tucatinib.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescription must be written by a oncologist.
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	For initiation, documentation of human epidermal growth factor receptor 2 (HER2) testing. Documentation of one or more prior anti-HER2-based regimens in the metastatic setting.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## TURALIO

---

### Products Affected

- Turalio

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis: symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to improvement with surgery in adults. Prior therapy used, result of prior therapy. If continuation, prior response to pexidartinib.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist.
<b>Coverage Duration</b>	3 months initiation and 1 year continuation
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## TYKERB

---

### Products Affected

- Tykerb

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	DIAGNOSIS, PRIOR AND CURRENT THERAPIES, TREATMENT RESPONSE
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## TYMLOS

---

### Products Affected

- Tymlos

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Not approved for a cumulative lifetime duration of abaloparatide and any other parathyroid hormone therapy (eg, teriparatide) of more than 2 years. Not approved for combination therapy of a PTH/PTHrP analog in combination with other osteoporosis agents.
<b>Required Medical Information</b>	Diagnosis, fracture history, prior therapy used and response to prior therapy. Required pretreatment testing: DXA, if not performed in the past two years: serum calcium, phosphorus, creatinine, alkaline phosphatase, albumin, 25-hydroxyvitamin D (25[OH]D), and, 24-hour urine calcium, creatinine (or fasting specimen for calcium/creatinine ratio) to evaluate for baseline hypercalciuria.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an endocrinologist.
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Documentation of an adequate trial on an oral bisphosphonate, or, if GI intolerant of oral bisphosphonates, use of a parenteral bisphosphonate - AND - an adequate trial on denosumab.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## UCERIS

---

### Products Affected

- budesonide oral tablet, delayed and ext. release

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Not approved for maintenance of remission or in patients with severe disease (UCDAI score = 10)
<b>Required Medical Information</b>	Diagnosis, other therapies tried and/or failed, including anti-inflammatory and immunosuppressant drugs
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by a gastroenterology specialist
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## UPTRAVI

---

### Products Affected

- Uptravi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Confirmation of diagnosis of PAH, other therapies tried, and documentation of response to therapy
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by a cardiologist or pulmonologist
<b>Coverage Duration</b>	3 months for initial, 1 year for continuation
<b>Other Criteria</b>	Must have PAH WHO group 1 . Prior to receiving treatment with Uptravi, patient must have a contraindication, intolerance to, or history of taking a PDE5 inhibitor (sildenafil or Adcirca) AND an ERA (bosentan or ambrisentan)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## UREA CYCLE DISORDER

---

### Products Affected

- Ravicti
- sodium phenylbutyrate oral powder

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months for initiation, 1 year for continuation
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## VALCHLOR

---

### Products Affected

- Valchlor

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## VALTOCO

---

### Products Affected

- Valtoco

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to diazepam.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescribing limited to a neurologist.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## VANCOMYCIN

---

### Products Affected

- vancomycin oral capsule 125 mg, 250 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 month
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## VASCEPA

---

### Products Affected

- Vascepa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used and result of prior therapy. For continuation, response to Vascepa.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescribed by, or in consultation with, a cardiologist, endocrinologist, or a physician who focuses in the treatment of CV risk management and/or lipid disorders.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Under CMS Review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## VELTASSA

---

### Products Affected

- Veltassa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Evidence of episodes of moderate to severe hyperkalemia (serum potassium level = 5.1 mEq/L) requiring discontinuation or dose reduction of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and/or aldosterone antagonists AND receives medication regimen that allows for practical administration of Veltassa 3 hours before or 3 hours after other oral medications
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## VENCLEXTA

---

### Products Affected

- Venclexta
- Venclexta Starting Pack

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis. Other treatments tried and response to therapies.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a hematologist or oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## VERZENIO

---

### Products Affected

- Verzenio

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	NA
<b>Required Medical Information</b>	Documentation of diagnosis, previous treatments, response to treatment, and LFTs.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by oncology
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## VITRAKVI

---

### Products Affected

- Vitrakvi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapies, and result of prior therapy.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## VIZIMPRO

---

### Products Affected

- Vizimpro

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to treatment.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## VOTRIENT

---

### Products Affected

- Votrient

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	DIAGNOSIS, OTHER THERAPIES TRIED AND FAILED, RESPONSE TO TREATMENT
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY AN ONCOLOGIST
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## WAKIX

---

### Products Affected

- Wakix

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to pitolisant.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescriber must be a neurologist or sleep specialist.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Adequate trial (at least 2 months) on one analeptic drug (i.e., modafinil or armodafinil) AND one CNS stimulant drug (i.e., amphetamine, methylphenidate or amphetamine/dextroamphetamine), unless intolerant or contraindicated.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## XATMEP

---

### Products Affected

- Xatmep

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior treatments, response to therapy
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist or rheumatologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Medical justification as to why member cannot use methotrexate tablets or injectable solution
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## XCOPRI

### Products Affected

- Xcopri
- Xcopri Titration Pack
- Xcopri Maintenance Pack

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Not approved for patients with familial short QT syndrome.
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to cenobamate.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	Prescription must be written by a neurologist.
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## XELJANZ

### Products Affected

- Xeljanz
- Xeljanz XR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, response to prior therapy. Documentation of negative TB test.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY A SPECIALIST (INCLUDING BUT NOT LIMITED TO RHEUMATOLOGIST OR GASTROENTEROLOGIST)
<b>Coverage Duration</b>	3 months for initiation, 2 years for continuation
<b>Other Criteria</b>	Prior to receiving treatment with Xeljanz for arthritis related condition, patient must have trial of or contraindication to at least one non-biologic DMARD (including but not limited to methotrexate, hydroxychloroquine, sulfasalazine, azathioprine). Dose adjustments and laboratory monitoring parameters should be adhered to as specified in the FDA approved drug labeling.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## XELJANZ22

---

### Products Affected

- Xeljanz XR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, response to prior therapy. Documentation of negative TB test.
<b>Age Restrictions</b>	Beneficiary is of appropriate age for use per FDA prescribing information.
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY A SPECIALIST (INCLUDING BUT NOT LIMITED TO RHEUMATOLOGIST OR GASTROENTEROLOGIST)
<b>Coverage Duration</b>	16 weeks
<b>Other Criteria</b>	Prior to receiving treatment with Xeljanz XR 22 mg for an ulcerative colitis condition, the patient must have an inadequate response or intolerance to tumor necrosis factor blockers. Dose adjustments and laboratory monitoring parameters should be adhered to as specified in the FDA approved drug labeling.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## XENAZINE

---

### Products Affected

- tetrabenazine

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	CONTRAINDICATED IN PATIENTS WITH HEPATIC DISEASE, THOSE TAKING MAOIS, OR WITH UNTREATED OR INADEQUATELY TREATED DEPRESSION
<b>Required Medical Information</b>	DIAGNOSIS OF HUNTINGTONS DISEASE
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY NEUROLOGIST
<b>Coverage Duration</b>	1 YEAR
<b>Other Criteria</b>	CYP2D6 GENOTYPING IS REQUIRED FOR PATIENTS WHO REQUIRE MORE THAN 50 MG PER DAY
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## XERMELO

---

### Products Affected

- Xermelo

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of carcinoid syndrome diarrhea AND diarrhea is inadequately controlled by a stable dose of somatostatin analog (SSA) therapy (e.g., octreotide, Somatuline Depot) for at least 3 months AND used in combination with SSA therapy.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist, endocrinologist, or gastroenterologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	For continuation of therapy-Documentation of a positive clinical response to Xermelo therapy AND Xermelo will continue to be used in combination with SSA therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## XGEVA

---

### Products Affected

- Xgeva

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies tried and/or failed
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## XIFAXAN

---

### Products Affected

- Xifaxan oral tablet 200 mg, 550 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Not covered for small intestinal bacterial over-growth (SIBO). Not covered for PROPHYLAXIS of traveler's diarrhea. For TREATMENT of traveler's diarrhea, not covered for diarrhea due to pathogens other than E. coli, and, not covered for diarrhea complicated by fever or blood in the stool.
<b>Required Medical Information</b>	Confirmation of diagnosis, other treatments tried and documentation of response to prior therapies.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months tx of traveler's diarrhea (TD) and recurrent C. diff. 1 year for all other conditions.
<b>Other Criteria</b>	For hepatic encephalopathy: treatment failure, intolerance, or contraindication to lactulose. For travelers diarrhea: treatment failure, intolerance, or contraindication to a fluoroquinolone (such as ciprofloxacin) and azithromycin. For IBS-D: treatment failure, intolerance, or contraindication to at least two of these drugs: loperamide, dicyclomine or diphenoxylate/atropine. For recurrent C. difficile: treatment failure, intolerance, or contraindication to vancomycin.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## XIIDRA

---

### Products Affected

- Xiidra

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Confirmation of diagnosis, other treatments tried, documentation of response to any prior therapies.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Initial, reauth: 12 months
<b>Other Criteria</b>	Failure, contraindication, or intolerance to Restasis at an optimal dose and frequency for at least 2 weeks
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

# XOLAIR

---

## Products Affected

- Xolair

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Under CMS Review.
<b>Required Medical Information</b>	For asthma: weight, IgE level at baseline, baseline FEV1, FEV1 following bronchodilator, medication history, ER visits, and hospitalizations. Evidence of a positive skin test or in-vitro reactivity to a perennial aeroallergen. For urticaria: documentation of persistence of hives associated with itching and prior treatments with outcome.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	pulmonologist, immunologist, allergist, or dermatologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Under CMS Review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## XOSPATA

---

### Products Affected

- Xospata

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapies, and result of prior therapy.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist or hematologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## XPOVIO

---

### Products Affected

- Xpovio

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Under CMS Review.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist or hematologist.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Under CMS Review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## XTANDI

---

### Products Affected

- Xtandi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to enzalutamide.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist or urologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Patient must undergo evaluation of seizure risk. For metastatic castration resistant prostate cancer (CRPC), patient must have a failure, intolerance, or contraindication to Zytiga prior to initiation of therapy with Xtandi.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## XURIDEN

---

### Products Affected

- Xuriden

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	The starting dose will be approved for 60 mg/kg once daily. Higher doses will be approved (up to 120 mg/kg once daily) in the following situations: Levels of orotic acid in urine remain above normal or increase above the usual or expected range for the patient OR Laboratory values (e.g., red blood cell or white blood cell indices) affected by hereditary orotic aciduria show evidence of worsening OR Worsening of other signs or symptoms of the disease
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months initial, 1 year continuation
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## XYREM

---

### Products Affected

- Xyrem

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Not to be used in patients concurrently using alcohol or sedative-hypnotic agents
<b>Required Medical Information</b>	Diagnosis, other therapies tried and failed
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by a sleep medicine specialist or neurologist
<b>Coverage Duration</b>	3 months for initiation, 6 months for continuation
<b>Other Criteria</b>	Dosing approved up to 9 grams per day
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A



## **ZEJULA**

---

### **Products Affected**

- Zejula

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis, prior therapies, and response to therapy
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist, endocrinologist, or gastroenterologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## ZELBORAF

### Products Affected

- Zelboraf

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	PATIENTS WITH WILD-TYPE BRAF MELANOMA, PREGNANCY
<b>Required Medical Information</b>	FOR METASTATIC MELANOMA: DOCUMENTATION OF DIAGNOSIS AND BRAF V600E MUTATION AS DETECTED USING AN FDA-APPROVED TEST. FOR ERDHEIM-CHESTER DISEASE: DOCUMENTATION OF DIAGNOSIS AND BRAF V600 MUTATION.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY AN ONCOLOGIST.
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	PERFORM DERMATOLOGICAL EVALUATIONS PRIOR TO INITIATION OF THERAPY AND EVERY 2 MONTHS WHILE ON THERAPY TO MONITOR FOR NEW PRIMARY MELANOMAS. MONITOR LIVER FUNCTION TESTS PRIOR TO INITIATION OF THERAPY AND AS CLINICALLY INDICATED THEREAFTER. MONITOR ECGs PRIOR TO INITIATION OF THERAPY, AT DAY 15, THEN MONTHLY, AND EVERY 3 MONTHS THEREAFTER. MONITOR PATIENTS FOR OPHTHALMOLOGIC REACTIONS AS CLINICALLY INDICATED.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## ZYDELIG

---

### Products Affected

- Zydelig

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	DIAGNOSIS, PRIOR TREATMENTS, RESPONSE TO THERAPY. FOR PATIENTS WITH CLL OR SLL, DOCUMENTATION OF PRIOR TREATMENT WITH IMBRUVICA. IF NO PREVIOUS FAILURE, RATIONALE AS TO WHY PREFERRED AGENT CANNOT BE USED
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PRESCRIPTION MUST BE WRITTEN BY ONCOLOGIST OR HEMATOLOGIST
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## ZYTIGA

---

### Products Affected

- abiraterone

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy used, result of prior therapy. If continuation, prior response to abiraterone.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescription must be written by an oncologist or urologist
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

## PART B VERSUS PART D

---

### Products Affected

- Abelcet
- acetylcysteine
- acyclovir sodium intravenous solution
- albuterol sulfate inhalation solution for nebulization
- AmBisome
- Aminosyn II 15 %
- Aminosyn-PF 7 % (sulfite-free)
- amphotericin B
- Astagraf XL
- Azasan
- azathioprine
- Bethkis
- bleomycin
- Brovana
- budesonide inhalation
- Clinimix 5%/D15W Sulfite Free
- Clinimix 4.25%/D10W Sulf Free
- Clinimix 4.25%/D5W Sulfit Free
- Clinimix 5%-D20W(sulfite-free)
- Clinimix E 2.75%/D5W Sulf Free
- Clinimix E 4.25%/D10W Sul Free
- Clinimix E 4.25%/D5W Sulf Free
- Clinimix E 5%/D15W Sulfit Free
- Clinimix E 5%/D20W Sulfit Free
- Clinisol SF 15 %
- cromolyn inhalation
- cyclophosphamide oral capsule
- cyclosporine modified
- cyclosporine oral capsule
- dexamethasone sodium phos (PF) injection solution
- dexamethasone sodium phosphate injection
- Engerix-B (PF) intramuscular syringe
- Engerix-B Pediatric (PF) intramuscular syringe
- everolimus (immunosuppressive)
- Freamine HBC 6.9 %
- Gengraf oral capsule 100 mg, 25 mg
- Gengraf oral solution
- granisetron HCl oral
- Hepatamine 8%
- Imovax Rabies Vaccine (PF)
- Intralipid intravenous emulsion 30 %
- ipratropium bromide inhalation
- ipratropium-albuterol
- levalbuterol HCl
- methylprednisolone oral tablet
- Millipred oral tablet
- mycophenolate mofetil
- mycophenolate sodium
- Myfortic
- Neoral
- Nephramine 5.4 %
- ondansetron
- ondansetron HCl oral
- pentamidine inhalation
- Perforomist
- Plenamine
- prednisolone oral solution 15 mg/5 mL
- prednisolone sodium phosphate oral solution 10 mg/5 mL, 15 mg/5 mL (3 mg/mL), 20 mg/5 mL (4 mg/mL), 25 mg/5 mL (5 mg/mL), 5 mg base/5 mL (6.7 mg/5 mL)
- Prednisone Intensol
- prednisone oral solution
- prednisone oral tablet
- Premasol 10 %
- Procalamine 3%
- Prograf oral granules in packet
- Pulmozyme
- RabAvert (PF)
- Rapamune
- Recombivax HB (PF) intramuscular suspension 10 mcg/mL, 40 mcg/mL
- Recombivax HB (PF) intramuscular syringe
- Sandimmune oral
- sirolimus
- tacrolimus oral

Prior Authorization Criteria

Health Alliance Plan 2021

Date Effective: 01/01/2021

- tobramycin in 0.225 % NaCl
- Travasol 10 %
- TrophAmine 10 %
- Yupelri
- Zortress oral tablet 1 mg

**Details**

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

**Index**

**A**

Abelcet ..... 221  
 Abilify Maintena..... 12  
 abiraterone..... 220  
 acetylcysteine..... 221  
 acyclovir sodium intravenous solution ... 221  
 adapalene topical cream..... 2  
 adapalene topical gel..... 2  
 adapalene topical solution..... 2  
 adapalene topical swab ..... 2  
 Adempas ..... 3  
 Afinitor Disperz ..... 4  
 Afinitor oral tablet 10 mg ..... 4  
 Aimovig Autoinjector ..... 5  
 albuterol sulfate inhalation solution for  
 nebulization..... 221  
 Alecensa..... 6  
 Alunbrig ..... 7  
 Alyq..... 129  
 AmBisome ..... 221  
 ambrisentan..... 136  
 Aminosyn II 15 %..... 221  
 Aminosyn-PF 7 % (sulfite-free)..... 221  
 amphotericin B..... 221  
 APOKYN..... 13  
 aprepitant..... 14  
 Aralast NP..... 1  
 Aranesp (in polysorbate) injection solution  
 100 mcg/mL, 200 mcg/mL, 25 mcg/mL,  
 300 mcg/mL, 40 mcg/mL, 60 mcg/mL 47,  
 48  
 Aranesp (in polysorbate) injection syringe  
 ..... 47, 48  
 Arcalyst..... 15  
 Aristada ..... 12  
 Aristada Initio ..... 12  
 armodafinil..... 10  
 Astagraf XL ..... 221  
 Aubagio..... 105  
 Auryxia ..... 16  
 Avita topical cream..... 182  
 Avita topical gel..... 182  
 Avonex intramuscular pen injector kit.... 105

Avonex intramuscular syringe kit..... 105  
 Ayvakit..... 17  
 Azasan..... 221  
 azathioprine..... 221  
**B**  
 Balversa..... 18  
 Baraclude oral solution ..... 62  
 Benlysta subcutaneous syringe ..... 19  
 Betaseron subcutaneous kit..... 105  
 Bethkis ..... 221  
 Bivigam..... 81  
 bleomycin..... 221  
 bosentan ..... 136  
 Bosulif oral tablet 100 mg, 400 mg, 500 mg  
 ..... 20  
 Braftovi oral capsule 75 mg..... 21  
 Briviact oral ..... 22  
 Brovana ..... 221  
 Brukinsa ..... 23  
 budesonide inhalation ..... 221  
 budesonide oral tablet, delayed and  
 ext.release..... 188  
**C**  
 Cabometyx ..... 24  
 Calquence..... 25  
 Caplyta ..... 12  
 Caprelsa oral tablet 100 mg, 300 mg ..... 26  
 Cerdelga ..... 57  
 chlorpromazine injection ..... 12  
 cinacalcet oral tablet 30 mg, 60 mg, 90 mg  
 ..... 151  
 Cinqair..... 27  
 Cinryze..... 64  
 Clinimix 5%/D15W Sulfite Free ..... 221  
 Clinimix 4.25%/D10W Sulf Free ..... 221  
 Clinimix 4.25%/D5W Sulfite Free ..... 221  
 Clinimix 5%-D20W(sulfite-free)..... 221  
 Clinimix E 2.75%/D5W Sulf Free ..... 221  
 Clinimix E 4.25%/D10W Sul Free ..... 221  
 Clinimix E 4.25%/D5W Sulf Free ..... 221  
 Clinimix E 5%/D15W Sulfite Free..... 221  
 Clinimix E 5%/D20W Sulfite Free..... 221  
 Clinisol SF 15 %..... 221

Clovique.....	183	Erivedge .....	45
Cometriq .....	28	Erleada .....	46
Copiktra.....	29	erlotinib.....	170
Corlanor .....	30	Esbriet oral capsule.....	135
Cosentyx (2 Syringes).....	31	Esbriet oral tablet 267 mg, 801 mg.....	135
Cosentyx Pen (2 Pens) .....	31	everolimus (antineoplastic).....	4
Cotellic.....	32	everolimus (immunosuppressive).....	221
cromolyn inhalation .....	221	Exjade .....	49
cyclophosphamide oral capsule .....	221	<b>F</b>	
cyclosporine modified.....	221	Fanapt.....	12
cyclosporine oral capsule.....	221	Farydak .....	50
<b>D</b>		Fasenra .....	51
dalfampridine .....	9	Fasenra Pen.....	51
Daliresp.....	34	fentanyl citrate buccal lozenge on a handle .....	180
Daurismo oral tablet 100 mg, 25 mg .....	35	Ferriprox oral tablet .....	52
deferasirox oral tablet, dispersible .....	49	Fetzima.....	11
Demser .....	36	Fintepla .....	53
dexamethasone sodium phos (PF) injection solution.....	221	Firdapse.....	8
dexamethasone sodium phosphate injection .....	221	Flebogamma DIF .....	81
diclofenac sodium topical gel 3 %.....	37	Freamine HBC 6.9 %.....	221
dihydroergotamine nasal.....	44	Fycompa oral suspension.....	54
Doptelet (10 tab pack).....	38	Fycompa oral tablet.....	54
Doptelet (15 tab pack).....	38	<b>G</b>	
Doptelet (30 tab pack).....	38	Galafold.....	55
Drizalma Sprinkle oral capsule, delayed rel sprinkle 20 mg, 30 mg, 40 mg, 60 mg ..	11	Gammagard Liquid.....	81
dronabinol .....	39	Gammagard S-D (IgA < 1 mcg/mL).....	81
Dupixent Pen.....	40	Gammaked injection solution 1 gram/10 mL (10 %), 10 gram/100 mL (10 %), 20 gram/200 mL (10 %), 5 gram/50 mL (10 %).....	81
Dupixent Syringe subcutaneous syringe 200 mg/1.14 mL, 300 mg/2 mL .....	40	Gammaflex .....	81
<b>E</b>		Gammaflex (with sorbitol).....	81
Enbrel Mini .....	41, 42	Gamunex-C.....	81
Enbrel subcutaneous recon soln.....	41, 42	Gattex 30-Vial.....	56
Enbrel subcutaneous syringe.....	41, 42	Gengraf oral capsule 100 mg, 25 mg .....	221
Enbrel SureClick.....	41, 42	Gengraf oral solution .....	221
Engerix-B (PF) intramuscular syringe ....	221	Gilenya oral capsule 0.5 mg.....	105
Engerix-B Pediatric (PF) intramuscular syringe.....	221	Gilotrif.....	58
entecavir.....	62	Glassia.....	1
Epidiolex.....	43	glatiramer .....	105
Epogen injection solution 2,000 unit/mL, 20,000 unit/2 mL, 20,000 unit/mL, 3,000 unit/mL, 4,000 unit/mL.....	47, 48	Glatopa.....	105
		Gralise .....	60
		Gralise 30-Day Starter Pack.....	60
		granisetron HCl oral.....	221



**H**

Haegarda .....	64
Hepatamine 8%.....	221
Hetlioz.....	65
Humira Pen .....	67, 68
Humira Pen Crohns-UC-HS Start.....	67, 68
Humira Pen Psor-Uveits-Adol HS.....	67, 68
Humira subcutaneous syringe kit 10 mg/0.2 mL, 20 mg/0.4 mL, 40 mg/0.8 mL .	67, 68
Humira(CF) Pedi Crohns Starter subcutaneous syringe kit 80 mg/0.8 mL, 80 mg/0.8 mL-40 mg/0.4 mL.....	67, 68
Humira(CF) Pen Crohns-UC-HS.....	67, 68
Humira(CF) Pen Psor-Uv-Adol HS....	67, 68
Humira(CF) Pen subcutaneous pen injector kit 40 mg/0.4 mL.....	67, 68
Humira(CF) subcutaneous syringe kit 10 mg/0.1 mL, 20 mg/0.2 mL, 40 mg/0.4 mL .....	67, 68

**I**

Ibrance.....	69
icatibant.....	64
Iclusig.....	70
Idhifa.....	71
imatinib oral tablet 100 mg, 400 mg.....	59
Imbruvica oral capsule 140 mg, 70 mg.....	72
Imbruvica oral tablet.....	72
Imovax Rabies Vaccine (PF) .....	221
Inbrija inhalation capsule, w/inhalation device .....	73
Increlex .....	74
Inlyta oral tablet 1 mg, 5 mg.....	76
Inqovi .....	77
Inrebic .....	78
Intralipid intravenous emulsion 30 %.....	221
Intron A injection.....	79
Invega Sustenna .....	12
Invega Trinza .....	12
ipratropium bromide inhalation .....	221
ipratropium-albuterol .....	221
Iressa .....	80

**J**

Jakafi.....	82
Juxtapid.....	66

Jynarque oral tablets, sequential 45 mg (AM)/ 15 mg (PM), 60 mg (AM)/ 30 mg (PM), 90 mg (AM)/ 30 mg (PM) .....	83
--	----

**K**

Kalydeco oral granules in packet.....	84
Kalydeco oral tablet .....	84
Kineret.....	85
Kisqali.....	86
Kisqali Femara Co-Pack .....	86
Korlym .....	87
Kuvan oral powder in packet 100 mg.....	88
Kuvan oral tablet,soluble .....	88

**L**

Latuda oral tablet 120 mg, 20 mg, 40 mg, 60 mg, 80 mg .....	12
Lenvima .....	89
Leukine injection recon soln.....	90
levalbuterol HCl.....	221
Libtayo .....	91
lidocaine topical adhesive patch,medicated 5 %.....	92
lidocaine topical ointment.....	92
Lokelma .....	93
Lonsurf.....	94
Lorbrena.....	95
Lynparza oral tablet .....	96

**M**

Mavenclad (10 tablet pack).....	97
Mavenclad (4 tablet pack).....	97
Mavenclad (5 tablet pack).....	97
Mavenclad (6 tablet pack).....	97
Mavenclad (7 tablet pack).....	97
Mavenclad (8 tablet pack).....	97
Mavenclad (9 tablet pack).....	97
Mavyret.....	63
Mayzent.....	98
Mekinist oral tablet 0.5 mg, 2 mg.....	100
Mektovi.....	101
methamphetamine .....	102
methylprednisolone oral tablet.....	221
miglustat.....	57
Millipred oral tablet .....	221
Mirvaso topical gel with pump .....	103
modafinil.....	10
Movantik.....	106

Prior Authorization Criteria  
 Health Alliance Plan 2021  
 Date Effective: 01/01/2021

Mulpleta .....	104	Oxervate .....	127
Myalept .....	107	<b>P</b>	
mycophenolate mofetil.....	221	Palynziq.....	128
mycophenolate sodium .....	221	Pegasys.....	79
Myfortic .....	221	Pegasys ProClick subcutaneous pen injector 180 mcg/0.5 mL .....	79
Mytesi .....	33	PegIntron subcutaneous kit 50 mcg/0.5 mL .....	160
<b>N</b>		Pemazyre.....	130
Natpara.....	108	pentamidine inhalation.....	221
Nayzilam.....	109	Perforomist.....	221
Neoral.....	221	Piqray .....	131
Nephramine 5.4 % .....	221	Plegridy.....	105
Nerlynx .....	110	Plenamine.....	221
Neupro.....	111	Pomalyst.....	132
Nexavar .....	112	prednisolone oral solution 15 mg/5 mL ..	221
Ninlaro .....	113	prednisolone sodium phosphate oral solution 10 mg/5 mL, 15 mg/5 mL (3 mg/mL), 20 mg/5 mL (4 mg/mL), 25 mg/5 mL (5 mg/mL), 5 mg base/5 mL (6.7 mg/5 mL) .....	221
nitisinone.....	123	Prednisone Intensol.....	221
Norditropin FlexPro .....	61	prednisone oral solution.....	221
Noxafil oral suspension.....	114	prednisone oral tablet.....	221
Nubeqa .....	115	Premasol 10 % .....	221
Nucala .....	116	Privigen.....	81
Nuedexta .....	117	Procalamine 3% .....	221
Nuplazid oral capsule.....	118	Procrit injection solution 10,000 unit/mL, 2,000 unit/mL, 20,000 unit/mL, 3,000 unit/mL, 4,000 unit/mL, 40,000 unit/mL .....	47, 48
Nuplazid oral tablet 10 mg.....	118	Prograf oral granules in packet .....	221
Nurtec ODT .....	119	Prolastin-C .....	1
Nutropin AQ Nuspin.....	61	Prolia.....	133
<b>O</b>		Promacta .....	134
Ocaliva .....	120	Pulmozyme .....	221
Octagam .....	81	Purixan .....	137
Odomzo.....	121	<b>Q</b>	
Ofev.....	135	Qinlock.....	138
ondansetron.....	221	<b>R</b>	
ondansetron HCl oral .....	221	RabAvert (PF).....	221
Opsumit.....	136	Rapamune .....	221
Orencia ClickJect.....	122	Ravicti.....	190
Orencia subcutaneous syringe 125 mg/mL, 50 mg/0.4 mL, 87.5 mg/0.7 mL .....	122	Recombivax HB (PF) intramuscular suspension 10 mcg/mL, 40 mcg/mL...	221
Orenitram .....	136		
Orfadin oral capsule 20 mg.....	123		
Orfadin oral suspension .....	123		
Orilissa .....	125		
Orkambi oral granules in packet.....	124		
Orkambi oral tablet .....	124		
Otezla .....	126		
Otezla Starter oral tablets,dose pack 10 mg (4)-20 mg (4)-30 mg (47).....	126		

Recombivax HB (PF) intramuscular syringe .....	221	Symproic .....	106
Repatha .....	139, 140	Synribo .....	164
Repatha Pushtronex .....	139, 140	<b>T</b>	
Repatha SureClick .....	139, 140	Tabrecta.....	165
Retevmo .....	141	tacrolimus oral .....	221
Revcovi .....	142	tadalafil (pulm. hypertension).....	129
Revlimid.....	143	Tafinlar.....	167
Rexulti.....	12	Tagrisso.....	168
Reyvow .....	144	Takhzyro .....	64
Rinvoq.....	145	Talzenna.....	169
Rozlytrek oral capsule 100 mg, 200 mg .	146	Targretin topical.....	171
Rubraca .....	147	Tasigna oral capsule 150 mg, 200 mg, 50	
Ruzurgi.....	8	mg .....	172
Rydapt.....	148	Tavalisse .....	173
<b>S</b>		tazarotene .....	174
Samsca oral tablet 15 mg .....	149	Tazorac topical cream 0.05 %.....	174
Sandimmune oral .....	221	Tazorac topical gel.....	174
Saphris.....	12	Tazverik .....	175
Savella oral tablet.....	150	Tecfidera .....	105
Savella oral tablets,dose pack .....	150	Tegsedi.....	176
Secuado .....	12	testosterone transdermal gel in metered-dose	
Signifor .....	152	pump 12.5 mg/ 1.25 gram (1 %), 20.25	
sildenafil (Pulmonary Arterial		mg/1.25 gram (1.62 %).....	177, 178
Hypertension) oral suspension for		testosterone transdermal gel in packet ...	177,
reconstitution 10 mg/mL.....	129	178	
sildenafil (Pulmonary Arterial		tetrabenazine .....	206
Hypertension) oral tablet 20 mg .....	129	Tibsovo .....	179
sirolimus.....	221	Tobi Podhaler inhalation capsule,	
Sirturo .....	153	w/inhalation device .....	75
Skyrizi subcutaneous syringe kit .....	154	tobramycin in 0.225 % NaCl .....	222
sodium phenylbutyrate oral powder.....	190	tolvaptan oral tablet 30 mg .....	149
Spritam.....	155	topiramate oral capsule, sprinkle .....	99
Sprycel .....	156	topiramate oral tablet .....	99
Stelara subcutaneous solution.....	157	Tracleer oral tablet for suspension.....	136
Stelara subcutaneous syringe 45 mg/0.5 mL,		Travasol 10 % .....	222
90 mg/mL.....	157	Trelstar intramuscular suspension for	
Stivarga .....	158	reconstitution.....	181
Sutent .....	159	tretinoin topical .....	182
Sylatron subcutaneous kit 200 mcg, 300		trientine .....	183
mcg.....	160	Trintellix .....	11
Symdeko .....	161	TrophAmine 10 %.....	222
SymlinPen 120.....	162	Tukysa.....	184
SymlinPen 60.....	162	Turalio.....	185
Sympazan oral film 10 mg, 20 mg, 5 mg	163	Tykerb.....	186
		Tymlos .....	187

Prior Authorization Criteria  
 Health Alliance Plan 2021  
 Date Effective: 01/01/2021

Tyvaso..... 136  
 Tyvaso Institutional Start Kit..... 136  
 Tyvaso Refill Kit..... 136  
 Tyvaso Starter Kit..... 136  
**U**  
 Uptravi ..... 189  
**V**  
 Valchlor..... 191  
 Valtoco ..... 192  
 vancomycin oral capsule 125 mg, 250 mg  
 ..... 193  
 Vascepa ..... 194  
 Veltassa ..... 195  
 Venclexta ..... 196  
 Venclexta Starting Pack..... 196  
 Ventavis ..... 136  
 Versacloz..... 12  
 Verzenio..... 197  
 Viibryd oral tablet..... 11  
 Viibryd oral tablets,dose pack 10 mg (7)-  
 mg (23)..... 11  
 Vitrakvi ..... 198  
 Vizimpro ..... 199  
 Votrient ..... 200  
 Vraylar oral capsule ..... 12  
 Vraylar oral capsule,dose pack ..... 12  
 Vyndamax ..... 166  
 Vyndaqel..... 166  
**W**  
 Wakix ..... 201

**X**  
 Xalkori ..... 6  
 Xatmep..... 202  
 Xcopri ..... 203  
 Xcopri Maintenance Pack..... 203  
 Xcopri Titration Pack..... 203  
 Xeljanz ..... 204  
 Xeljanz XR..... 204, 205  
 Xermelo..... 207  
 Xgeva ..... 208  
 Xifaxan oral tablet 200 mg, 550 mg ..... 209  
 Xiidra ..... 210  
 Xolair ..... 211  
 Xospata ..... 212  
 Xpovio..... 213  
 Xtandi..... 214  
 Xuriden ..... 215  
 Xyrem ..... 216  
**Y**  
 Yupelri ..... 222  
**Z**  
 Zavesca ..... 57  
 Zejula ..... 217  
 Zelboraf..... 218  
 Zemaira ..... 1  
 Zepatier ..... 63  
 zonisamide ..... 99  
 Zortress oral tablet 1 mg ..... 222  
 Zydelig ..... 219  
 Zykadia oral tablet ..... 6